Difference between revisions of "Chronic lymphocytic leukemia"
Warner-admin (talk | contribs) m |
Warner-admin (talk | contribs) m |
||
Line 2,372: | Line 2,372: | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Acetaminophen (Tylenol)]] 1000 mg prior to each infusion | + | *[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to each infusion |
− | *[[Cetirizine (Zyrtec)]] 10 mg prior to each infusion | + | *[[Cetirizine (Zyrtec)]] (or equivalent) 10 mg PO once prior to each infusion |
*[[Prednisolone (Millipred)]] 100 mg (or [[Steroid conversions|equivalent]]) PO once before infusions 1, 2, and 9 (question whether this was a typo), reduced or omitted if initial infusions well-tolerated | *[[Prednisolone (Millipred)]] 100 mg (or [[Steroid conversions|equivalent]]) PO once before infusions 1, 2, and 9 (question whether this was a typo), reduced or omitted if initial infusions well-tolerated | ||
Line 3,552: | Line 3,552: | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Acetaminophen (Tylenol)]] 1000 mg prior to each infusion | + | *[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to each infusion |
− | *[[Cetirizine (Zyrtec)]] | + | *[[Cetirizine (Zyrtec)]] (or equivalent [[:Category:Antihistamines|antihistamine]]) 10 mg PO once prior to each infusion |
'''Up to 2 years (24 doses)''' | '''Up to 2 years (24 doses)''' |
Revision as of 01:27, 26 January 2019
Section editor | |
---|---|
Sanjai Sharma, MD Visalia, CA |
Are you looking for a regimen but can't find it here? It is possible that we've moved it to the historical regimens page. If you still can't find it, please let us know so we can add it!
86 regimens on this page
133 variants on this page
|
Guidelines
ASBMT
- 2016: Kharfan-Dabaja et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation
ESMO
- 2016: Ladetto et al. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia PubMed
- 2015: Eichhorst et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2013: Ghielmini et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) PubMed
International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
- 2018: Hallek et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL PubMed
Older
- 2008: Hallek et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- 1996: Cheson et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment PubMed
NCCN
First-line therapy, randomized data
Alemtuzumab monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Hillmen et al. 2007 (CAM 307) | Phase III (E) | Chlorambucil | Superior PFS |
This regimen was intended for patients who were at least 18 years old with flow cytometry–confirmed diagnosis of B-cell CLL, Rai stage I through IV with evidence of progression according to the National Cancer Institute Working Group (NCI-WG) 1996 criteria, no previous chemotherapy for CLL, a life expectancy of at least 12 weeks, WHO performance status of 0 to 2, and adequate renal and liver function.
Chemotherapy
- Alemtuzumab (Campath) as follows:
- 3 mg IV once per day, then increased as tolerated in terms of infusion reactions to 10 mg IV once per day, and then to 30 mg IV once per day
- Once 30 mg dose is tolerated: 30 mg IV over 2 hours, 3 times per week
Supportive medications
- See references for details, as they differ by paper.
- Diphenhydramine (Benadryl) 50 mg PO once 30 minutes prior to Alemtuzumab (Campath)
- Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to Alemtuzumab (Campath)
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO 3 times per week, starting on day 8, continuing at a minimum until 2 months after treatment is complete
- Famciclovir (Famvir) 250 mg PO twice per day, starting on day 8, continuing at a minimum until 2 months after treatment is complete
Up to 12 to 16 weeks of therapy
Total course varies depending on reference.
References
- Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10;25(35):5616-23. Epub 2007 Nov 5. link to original article contains protocol PubMed
Bendamustine monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Knauf et al. 2009 | Phase III (E) | Chlorambucil | Superior PFS |
This regimen was intended for previously untreated CLL patients up to 75 years of age with Binet stage B or C disease in need for treatment per the NCI-WG guidelines or IWCLL guidelines.
Chemotherapy
- Bendamustine 100 mg/m2 IV once per day on days 1 & 2
28-day cycle for 6 cycles
References
- Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84. Epub 2009 Aug 3. link to original article contains verified protocol PubMed
- Update: Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, Montillo M. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012 Oct;159(1):67-77. Epub 2012 Aug 4. link to original article PubMed
- Retrospective: Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. link to PMC article PubMed
BR
back to top |
BR: Bendamustine & Rituximab
R-B: Rituximab & Bendamustine
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Fischer et al. 2012 (GCLLSG CLL2M) | Phase II | ||
Eichhorst et al. 2016 (GCLLSG CLL10) | Phase III (E) | FCR | Seems to have inferior PFS |
Michallet et al. 2018 (MABLE) | Phase IIIb (E) | R-Clb | Superior PFS |
Chemotherapy
- Bendamustine 90 mg/m2 IV once per day on days 1 & 2
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 0
- Subsequent cycles: 500 mg/m2 IV once on day 1
28-day cycle for up to 6 cycles based on response and toxicity
References
- GCLLSG CLL2M: Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012 Sep 10;30(26):3209-16. Epub 2012 Aug 6. link to original article contains verified protocol PubMed
- Retrospective: Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. link to PMC article PubMed
- GCLLSG CLL10: Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. Epub 2016 May 20. link to original article PubMed
- MABLE: Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1. link to original article contains verified protocol link to PMC article PubMed
CC
back to top |
CC: Cladribine, Cyclophosphamide
Variant #1, 0.36/650
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Robak et al. 2006 (PALG CLL2) | Phase III (E) | 1. Cladribine | Might have superior CR rate |
2. CMC | Seems to have inferior CR rate |
Chemotherapy
- Cladribine (Leustatin) 0.12 mg/kg IV over 2 hours once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 650 mg/m2 IV once on day 1
Supportive medications
- No routine prophylactic antibiotics, antiviral agents, or growth factor administration was planned.
28-day cycle for up to 6 cycles
Variant #2, 0.36/750
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Robak et al. 2010 (PALG-CLL3) | Phase III (E) | FC | Seems not superior |
Chemotherapy
- Cladribine (Leustatin) 0.12 mg/kg IV over 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 250 mg/m2 IV over 30 to 60 minutes once per day on days 1 to 3
Supportive medications
- "No routine prophylaxis with antibiotics, antiviral agents, or growth factors."
28-day cycle for up to 6 cycles
References
- PALG CLL2: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21. link to original article contains verified protocol PubMed
- Update: Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14. link to original article PubMed
- PALG-CLL3: Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010 Apr 10;28(11):1863-9. Epub 2010 Mar 8. link to original article contains verified protocol PubMed
Chlorambucil & Obinutuzumab
back to top |
GClb: GA101 (Obinutuzumab) & Chlorambucil
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Goede et al. 2014 (GCLLSG CLL11) | Phase III (E) | 1. Chlorambucil | Superior OS |
2. Chlorambucil & Rituximab | Superior PFS |
Chemotherapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once per day on days 8 & 15
- Cycles 2 to 6: 1000 mg IV once on day 1
- Chlorambucil (Leukeran) 0.5 mg/kg PO once per day on days 1 & 15
28-day cycle for 6 cycles
References
- GCLLSG CLL11: Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. Epub 2014 Jan 8. link to original article contains verified protocol PubMed
- Update: Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. Epub 2015 Jan 30. link to original article PubMed
Chlorambucil & Ofatumumab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Hillmen et al. 2015 (COMPLEMENT 1) | Phase III (E) | Chlorambucil | Superior PFS |
Chemotherapy
- Chlorambucil (Leukeran) 10 mg/m2 PO once per day on days 1 to 7
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once on day 8
- Cycle 2 onwards: 1000 mg IV once on day 1
Supportive medications
- Premedication for Ofatumumab (Arzerra) included Acetaminophen (Tylenol), antihistamines, and glucocorticoids (no doses or further information provided)
28-day cycle for a minimum of 3 cycles, and then given until best response up to a maximum of 12 cycles
References
- COMPLEMENT 1: Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, Doubek M, Panagiotidis P, Kimby E, Schuh A, Pettitt AR, Boyd T, Montillo M, Gupta IV, Wright O, Dixon I, Carey JL, Chang CN, Lisby S, McKeown A, Offner F; COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015 May 9;385(9980):1873-83. Epub 2015 Apr 13. link to original article contains protocol PubMed
Chlorambucil & Rituximab
back to top |
RClb: Rituximab & Chlorambucil
CLB-R: ChLoramBucil & Rituximab
Variant #1, Clb 0.5 mg/kg q2wk
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Goede et al. 2014 (GCLLSG CLL11) | Phase III (E) | 1. Chlorambucil | Superior PFS |
2. Chlorambucil & Obinutuzumab | Inferior PFS |
Chemotherapy
- Chlorambucil (Leukeran) 0.5 mg/kg PO once per day on days 1 & 15
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
28-day cycle for 6 cycles
Variant #2, Clb 8 mg/m2/d, 1 week out of 4
Study | Evidence |
---|---|
Foà et al. 2014 | Non-randomized portion of RCT |
Chemotherapy
- Chlorambucil (Leukeran) 8 mg/m2/day PO once per day on days 1 to 7
- Rituximab (Rituxan) as follows:
- Cycle 3: 375 mg/m2 IV once on day 1
- Subsequent cycles: 500 mg/m2 IV once on day 1
28-day cycle for up to 8 cycles
Subsequent treatment
- Responders (PR or better): Observation versus Rituximab maintenance
Variant #3, Clb 10 mg/m2/d, 1 week out of 4
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Hillmen et al. 2014 (NCRI CLL208) | Phase II | ||
Michallet et al. 2018 (MABLE) | Phase IIIb (E) | BR | Inferior PFS |
Chemotherapy
- Chlorambucil (Leukeran) 10 mg/m2 PO once per day on days 1 to 7
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
28-day cycles for 6 cycles
Subsequent treatment
- NCRI CLL208: Patients not achieving CR could have up to 6 more cycles of chlorambucil alone
- MABLE: Patients not achieving CR could have up to 6 more cycles of chlorambucil alone or until CR
References
- GCLLSG CLL11: Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. Epub 2014 Jan 8. link to original article contains verified protocol PubMed
- Update: Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. Epub 2015 Jan 30. link to original article PubMed
- Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014 May;89(5):480-6. Epub 2014 Feb 18. link to original article contains verified protocol PubMed
- NCRI CLL08: Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014 Apr 20;32(12):1236-41. Epub 2014 Mar 17. link to original article contains verified protocol link to PMC article PubMed
- MABLE: Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1. link to original article contains verified protocol link to PMC article PubMed
Cladribine monotherapy
back to top |
Variant #1, 0.36
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Robak et al. 2006 (PALG CLL2) | Phase III (C) | 1. CC | Might have inferior CR rate |
2. CMC | Inferior CR rate | ||
Mulligan et al. 2014 | Phase III (E) | 1. Chlorambucil 2. Fludarabine | Superior PFS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm. Dosing details for Mulligan et al. 2014 were not available in the abstract.
Chemotherapy
- Cladribine (Leustatin) 0.12 mg/kg IV over 2 hours once per day on days 1 to 5
Supportive medications
- No routine prophylactic antibiotics, antiviral agents, or growth factor administration was planned.
28-day cycle for up to 6 cycles
Variant #2, 0.7
Study | Evidence |
---|---|
Saven et al. 1995 | Phase II |
Chemotherapy
- Cladribine (Leustatin) 0.1 mg/m2/day IV continuous infusion on days 1 to 7 (total dose per cycle: 0.7 mg/m2)
28 to 35-day cycles, repeated until maximum response or limiting toxicity
References
- Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995 Mar;13(3):570-4. link to original article contains protocol PubMed
- PALG CLL2: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21. link to original article contains verified protocol PubMed
- Update: Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14. link to original article PubMed
- Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, Juliusson G; Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg). Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Dec;55(12):2769-77. Epub 2014 Apr 16. link to original article PubMed
CMC
back to top |
CMC: Cladribine, Mitoxantrone, Cyclophosphamide
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Robak et al. 2006 (PALG CLL2) | Phase III (E) | 1. Cladribine | Superior CR rate |
2. CC | Seems to have superior CR rate |
Chemotherapy
- Cladribine (Leustatin) 0.12 mg/kg IV over 2 hours once per day on days 1 to 3
- Mitoxantrone (Novantrone) 10 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 650 mg/m2 IV once on day 1
28-day cycle for up to 6 cycles
References
- PALG CLL2: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21. link to original article contains protocol PubMed
FCA
back to top |
FCA: Fludarabine, Cyclophosphamide, Alemtuzumab
FCCam: Fludarabine, Cyclophosphamide, Campath (Alemtuzumab)
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Lepretre et al. 2012 (GOELAMS CLL2007FMP) | Phase III (E) | FCR | Seems not superior |
Geisler et al. 2014 (HOVON-68) | Phase III (E) | FC | Superior PFS |
GOELAMS CLL2007FMP was halted prematurely due to excess mortality. In HOVON-68, this regimen was intended for patients with previously untreated CLL diagnosed and in need of treatment according to the National Cancer Institute guidelines, 18 to 75 years of age, with WHO performance status less than 3 and no severe comorbidities, with high-risk CLL as defined by the presence of either unmutated IGHV, 17p deletion, 11q deletion, or trisomy 12 by FISH.
Chemotherapy
- Fludarabine (Fludara) 40 mg/m2 PO once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 250 mg/m2 PO once per day on days 1 to 3
- Alemtuzumab (Campath) as follows:
- Cycle 1: 30 mg SC once per day on days -1, 0, and 1
- Subsequent cycles: 30 mg SC once on day 1
Supportive medications
- Cotrimoxazole 400/80 mg PO once per day until 6 months after end of treatment
- Acyclovir (Zovirax) 400 mg PO three times per day until 3 months after end of treatment
OR
- Valacyclovir (Valtrex) 500 mg PO twice per day until 3 months after end of treatment
28-day cycle for 6 cycles
References
- Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14. link to original article PubMed
- Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MC, Doorduijn J, Ghidey Alemayehu W, van Oers MH. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood. 2014 May 22;123(21):3255-62. Epub 2014 Apr 15. link to original article contains verified protocol PubMed
FCM
back to top |
FCM: Fludarabine, Cyclophosphamide, Mitoxantrone
Variant #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Hillmen et al. 2011 (NCRI CLL201) | Randomized Phase II (C) | FCM-R | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
- Fludarabine (Fludara) 24 mg/m2 PO once per day on days 1 to 5
- Cyclophosphamide (Cytoxan) 150 mg/m2 PO once per day on days 1 to 5
- Mitoxantrone (Novantrone) 6 mg/m2 IV once on day 1
28-day cycle for 6 cycles
Variant #2
Study | Evidence |
---|---|
Bosch et al. 2008 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV over 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 200 mg/m2 IV over 60 minutes once per day on days 1 to 3
- Mitoxantrone (Novantrone) 6 mg/m2 IV over 30 minutes once on day 1
Supportive medications
- Granulocyte colony-stimulating factor 300 mcg SC once per day on days 1 to 7
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 5
28-day cycle for 6 cycles
References
- Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008 Jan 1;14(1):155-61. link to original article contains verified protocol PubMed
- Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C; NCRI CLL Sub-Group. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. Br J Haematol. 2011 Mar;152(5):570-8. Epub 2011 Jan 14. link to original article contains verified protocol PubMed
FCR
back to top |
FCR: Fludarabine, Cyclophosphamide, Rituximab
R-FC: Rituximab, Fludarabine, Cyclophosphamide
Variant #1, 25/250/375-500
Study | Evidence | Comparator | Efficacy | Toxicity |
---|---|---|---|---|
Keating et al. 2005 | Phase II | |||
Hallek et al. 2010 (GCLLSG CLL8) | Phase III (E) | FC | Superior OS (*) | Equivalent HRQoL |
Lepretre et al. 2012 (GOELAMS CLL2007FMP) | Phase III (C) | FCCam | Seems not superior | |
Schweighofer et al. 2013 (GCLLSG CLL7) | Phase III (E) | Observation | Superior EFS | |
Eichhorst et al. 2016 (GCLLSG CLL10) | Phase III (C) | BR | Seems to have superior PFS |
Note: efficacy for GCLLSG CLL8 is based on the updated 2016 results.
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 250 mg/m2 IV once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 0
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
Supportive medications
- Note: these vary according to reference.
- Diphenhydramine (Benadryl) 25 mg IV once 30 minutes prior to Rituximab (Rituxan)
- Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to Rituximab (Rituxan)
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 7 of cycle 1
- Some patients received:
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO twice per week
- Valacyclovir (Valtrex) 500 mg PO once per day
- PCP (Pneumocystis jirovecii pneumonia) prophylaxis recommended for severe leukopenia greater than 7 days
- No routine prophylaxis with antiviral medications or G-CSF
28-day cycle for 6 cycles
Variant #2, 25/250/500
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Awan et al. 2014 (LUCID) | Phase III (C) | FCR+L | Seems not superior |
Chemotherapy
- Fludarabine (Fludara) as follows:
- Cycle 1: 25 mg/m2 IV over at least 10 to 30 minutes once per day on days 2 to 4
- Cycle 2 to 6: 25 mg/m2 IV over at least 10 to 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) as follows:
- Cycle 1: 250 mg/m2 IV over at least 10 to 30 minutes once per day on days 2 to 4
- Cycle 2 to 6: 250 mg/m2 IV over at least 10 to 30 minutes once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 50 mg/m2 IV over 4 hours once on day 1, then 450 mg/m2 IV once on day 3
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
Supportive medications
- Cotrimoxazole or equivalent
- Acyclovir (Zovirax) 400 mg PO twice per day or equivalent
- Growth factors at physician discretion
28-day cycle for 6 cycles
Variant #3, 20/150/375-500 ("FCR-Lite")
Study | Evidence |
---|---|
Foon et al. 2009 | Phase II |
Chemotherapy
- Fludarabine (Fludara) as follows:
- Cycle 1: 20 mg/m2 IV over 30 minutes once per day on days 2 to 4
- Cycles 2 to 6: 20 mg/m2 IV over 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) as follows:
- Cycle 1: 150 mg/m2 IV over 60 minutes once per day on days 2 to 4
- Cycles 2 to 6: 150 mg/m2 IV over 60 minutes once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1, then 500 mg/m2 IV once on day 14
- Cycles 2 to 6: 500 mg/m2 IV once per day on days 1 & 14
Supportive medications
- Diphenhydramine (Benadryl) 25 mg PO prior to Rituximab (Rituxan)
- Acetaminophen (Tylenol) 650 mg PO prior to Rituximab (Rituxan)
- Dexamethasone (Decadron) 10 mg IV or PO prior to Rituximab (Rituxan)
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 10 of cycle 1
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO twice per day three times per week, for 6 months past last dose of chemotherapy
- Acyclovir (Zovirax) 400 mg PO three times per day, for 6 months past last dose of chemotherapy
- Filgrastim (Neupogen) or Pegfilgrastim (Neulasta) 24 hours after chemo (details not provided)
28-day cycles for 6 cycles
Subsequent treatment
Variant #4, 40/250/375-500, oral FC
Study | Evidence |
---|---|
Dartigeas et al. 2017 (CLL 2007 SA) | Non-randomized portion of RCT |
Chemotherapy
- Fludarabine (Fludara) 40 mg/m2 PO once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 250 mg/m2 PO once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1, then 500 mg/m2 IV once on day 14
- Cycle 2: 500 mg/m2 IV once per day on days 1 & 14
- Cycles 3 & 4: 500 mg/m2 IV once on day 1
1-month cycle for 4 cycles
Subsequent treatment
- Rituximab maintenance versus observation
Variant #5, 25/250/375
Study | Evidence |
---|---|
Tam et al. 2006 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV over 15 to 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 250 mg/m2 IV over 15 to 30 minutes once per day on days 1 to 3
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for up to 6 cycles or "attainment of maximum response"
Variant #6, 24/150/375-500, oral FC
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Munir et al. 2017 (ADMIRE) | Randomized Phase IIB (C) | FCM-R | Seems not superior |
Howard et al. 2017 (ARCTIC) | Randomized Phase IIB (C) | FCM-miniR | Superior CR rate |
Note: in contrast to other variants, FC is given over 5 days not 3.
Chemotherapy
- Fludarabine (Fludara) 24 mg/m2 PO once per day on days 1 to 5
- Cyclophosphamide (Cytoxan) 150 mg/m2/day PO on days 1 to 5
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
28-day cycle for 6 cycles
References
- Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4079-88. Epub 2005 Mar 14. link to original article contains verified protocol PubMed
- Update: Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15;112(4):975-80. Epub 2008 Apr 14. link to original article link to PMC article PubMed
- Update and Subgroup Analysis: Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016 Jan 21;127(3):303-9. Epub 2015 Oct 22. link to original article link to PMC article PubMed
- Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 2006 Jun 1;106(11):2412-20. link to original article contains verified protocol PubMed
- Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Feb 1;27(4):498-503. Epub 2008 Dec 15. link to original article contains verified protocol PubMed
- Update: Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012 Mar 29;119(13):3184-5. link to original article PubMed
- GCLLSG CLL8: Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74. link to original article contains verified protocol PubMed
- Update: Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15. Epub 2015 Oct 20. link to original article PubMed
- HRQoL analysis: Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Feb;58(2):399-407. Epub 2016 Jun 29. link to original article PubMed
- Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14. link to original article PubMed
- Abstract: Carmen D Schweighofer, MD, Florence Cymbalista, MD, Carolin Müller, MD, Raymonde Busch, PhD, Raphael Porcher, PhD, Petra Langerbeins, MD, Bruno Cazin, MD, Anna-Maria Fink, MD, Brigitte Dreyfus, MD, Stefan Ibach, Stéphane Leprêtre, MD, Kirsten Fischer, MD, Ursula Vehling-Kaiser, MD, Barbara Eichhorst, MD, Manuela A. Bergmann, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Veronique Leblond, MD, Michael Hallek, MD, and Vincent Levy, MD, PhD. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. 2013 ASH Annual Symposium abstract 524 link to abstract
- Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov;167(4):466-77. Epub 2014 Aug 8. link to original article contains verified protocol PubMed
- GCLLSG CLL10: Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. Epub 2016 May 20. link to original article PubMed
- ADMIRE: Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 2017 Oct;31(10):2085-2093. Epub 2017 Apr 20. link to original article contains verified protocol PubMed
- ARCTIC: Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, Hockaday A, Allsup DJ, Marshall S, Duncombe AS, O'Dwyer JL, Smith AF, Longo R, Varghese A, Hillmen P. Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 2017 Nov;31(11):2416-2425. Epub 2017 Mar 24. link to original article contains verified protocol in supplement PubMed
- Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018 Feb;5(2):e82-e94. Epub 2017 Dec 20. link to original article contains protocol PubMed
Fludarabine & Alemtuzumab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Elter et al. 2011 (CAM 314) | Phase III (E) | Fludarabine | Seems to have superior OS |
Chemotherapy
28-day cycle for up to 6 cycles
References
- CAM 314: Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011 Dec;12(13):1204-13. Epub 2011 Oct 10. link to original article PubMed
Ibrutinib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
O'Brien et al. 2013 (PCYC-1102) | Phase Ib/II | ||
Farooqui et al. 2014 (NHLBI 12-H-0035) | Phase II | ||
Burger et al. 2015 (RESONATE-2) | Phase III (E) | Chlorambucil | Seems to have superior OS (*) |
Langerbeins et al. 2015 (CLL12) | Phase III (E) | Placebo | TBD |
Woyach et al. 2018 (Alliance A041202) | Phase III (E) | BR | Superior PFS |
Ibrutinib & Rituximab | Seems not superior |
PCYC-1102 was intended for elderly patients. Although both 420 mg and 840 mg doses were planned, the 840 mg cohort was closed due to findings of comparable efficacy in other studies. NHLBI 12-H-0035 was intended for patients with p.TP53 aberrations. RESONATE-2 was intended for patients older than 65 years. CLL12 was intended for patients with asymptomatic Binet stage A CLL. Reported efficacy for RESONATE-2 is based on the 2018 update.
Chemotherapy
- Ibrutinib (Imbruvica) 420 mg PO once per day
28-day cycles
References
- PCYC-1102: O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan;15(1):48-58. Epub 2013 Dec 10. link to original article contains verified protocol link to PMC article PubMed
- Update: Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16;125(16):2497-506. Epub 2015 Feb 19. link to original article link to PMC article PubMed
- Update: O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 Apr 26;131(17):1910-1919. Epub 2018 Feb 2. link to original article PubMed
- NHLBI 12-H-0035: Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015 Feb;16(2):169-76. Epub 2014 Dec 31. link to original article contains protocol link to PMC article PubMed
- RESONATE-2: Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec 17;373(25):2425-37. Epub 2015 Dec 6. link to original article contains verified protocol link to PMC article PubMed
- Update: Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 Sep;103(9):1502-1510. Epub 2018 Jun 7. link to original article link to PMC article PubMed
- Abstract: Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD and Michael Hallek, MD. Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. ASH Annual Meeting 2015 Abstract 2934. link to abstract
- Alliance A041202: Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 Dec 27;379(26):2517-2528. Epub 2018 Dec 1. link to original article contains protocol PubMed
Ibrutinib & Obinutuzumab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Moreno et al. 2018 (iLLUMINATE) | Phase III (E) | G-Clb | Superior PFS |
Chemotherapy
- Ibrutinib (Imbruvica) 420 mg PO once per day
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once per day on days 8 & 15
- Cycles 2 to 6: 1000 mg IV once on day 1
28-day cycles
References
- iLLUMINATE: Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2018 Nov 30. [Epub ahead of print] link to original article contains protocol PubMed
Obinutuzumab monotherapy
back to top |
Variant #1, standard-dose (1000 mg)
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Byrd et al. 2015 | Randomized Phase II (C) | High-dose obinutuzumab | Might have inferior ORR rate |
Chemotherapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once per day on days 8 & 15
- Cycle 2 onwards: 1000 mg IV once on day 1
Supportive medications
- Acetaminophen (Tylenol) 650 to 1000 mg PO 30 to 60 minutes prior to each infusion
- Antihistamine "such as" Diphenhydramine (Benadryl) 50 to 100 mg PO 30 to 60 minutes prior to each infusion
- Prednisolone (Millipred) 100 mg "or equivalent" IV before each of the first three infusions, afterwards at the discretion of treating physician
21-day cycle up to 8 cycles
Variant #2, high-dose (2000 mg)
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Byrd et al. 2015 | Randomized Phase II (E) | Standard-dose obinutuzumab | Might have superior ORR rate |
Chemotherapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: either of the following:
- 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once on day 3, then 2000 mg IV once per day on days 8 & 15
- 100 mg IV once on day 1, then 1900 mg IV once on day 2, then 2000 mg IV once per day on days 8 & 15
- Cycle 2 onwards: 2000 mg IV once on day 1
- Cycle 1: either of the following:
Supportive medications
- Acetaminophen (Tylenol) 650 to 1000 mg PO 30 to 60 minutes prior to each infusion
- Antihistamine "such as" Diphenhydramine (Benadryl) 50 to 100 mg PO 30 to 60 minutes prior to each infusion
- Prednisolone (Millipred) 100 mg "or equivalent" IV before each of the first three infusions, afterwards at the discretion of treating physician
21-day cycle up to 8 cycles
References
- Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016 Jan 7;127(1):79-86. Epub 2015 Oct 15. link to original article contains verified protocol link to PMC article PubMed
Observation
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Dighiero et al. 1998 (FRE-CLL-85) | Phase III (C) | 1. Chlorambucil | Seems to have inferior PFS |
2. Chlorambucil & Prednisone | Inferior PFS | ||
Bergmann et al. 2013 (GCLLSG CLL1) | Phase III (C) | Fludarabine | Inferior PFS |
Schweighofer et al. 2013 (GCLLSG CLL7) | Phase III (C) | FCR | Inferior EFS |
Langerbeins et al. 2015 (CLL12) | Phase III (C) | Ibrutinib | TBD |
No active treatment, also known as "watchful waiting".
References
- FRE-CLL-85: Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P. Chlorambucil in indolent chronic lymphocytic leukemia: French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998 May 21;338(21):1506-14. link to original article contains verified protocol PubMed
- Abstract: Manuela A. Bergmann, MD, Raymonde Busch, PhD, Barbara Eichhorst, MD, Andreas Buehler, MD, Norbert Fischer, MD, Michael J Eckart, MD, Ursula Vehling-Kaiser, MD, Ulrich Jäger, MD, Georg Hopfinger, MD, Clemens Wendtner, MD, Kirsten Fischer, MD, Bertold Emmerich, MD, Hartmut Döhner, MD, Michael Hallek, M.D. Ph.D. and Stephan Stilgenbauer, MD. Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG). Blood 2013 122:4127. link to abstract
- Abstract: Carmen D Schweighofer, MD, Florence Cymbalista, MD, Carolin Müller, MD, Raymonde Busch, PhD, Raphael Porcher, PhD, Petra Langerbeins, MD, Bruno Cazin, MD, Anna-Maria Fink, MD, Brigitte Dreyfus, MD, Stefan Ibach, Stéphane Leprêtre, MD, Kirsten Fischer, MD, Ursula Vehling-Kaiser, MD, Barbara Eichhorst, MD, Manuela A. Bergmann, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Veronique Leblond, MD, Michael Hallek, MD, and Vincent Levy, MD, PhD. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. 2013 ASH Annual Symposium abstract 524 link to abstract
- Abstract: Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD and Michael Hallek, MD. Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. ASH Annual Meeting 2015 Abstract 2934. link to abstract
First-line therapy, non-randomized or retrospective data
Alemtuzumab & Methylprednisolone
back to top |
Regimen
Study | Evidence |
---|---|
Pettitt et al. 2012 (NCRI CLL206) | Phase II |
Chemotherapy
16 week course
References
- NCRI CLL206: Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012 May 10;30(14):1647-55. Epub 2012 Apr 9. link to original article PubMed
Bendamustine & Obinutuzumab
back to top |
G-B: Gazyva (Obinutuzumab), Bendamustine
Regimen
Study | Evidence | Efficacy |
---|---|---|
Brown et al. 2015 (GALTON) | Phase 1b, 20 pts | ORR: 90% |
Chemotherapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once on days 8 & 15
- Cycles 2 to 6: 1000 mg IV once on day 1
- Bendamustine as follows:
- Cycle 1: 90 mg/m2 IV once per day on days 2 & 3
- Cycles 2 to 6: 90 mg/m2 IV once per day on days 1 &2
Supportive medications
- Acetaminophen (Tylenol) (dose not specified) prior to each Obinutuzumab (Gazyva) infusion
- Antihistamine e.g. Diphenhydramine (Benadryl) prior to each Obinutuzumab (Gazyva) infusion
- Highly potent corticosteroid (e.g. Prednisolone (Millipred) 100 mg IV) before first Obinutuzumab (Gazyva) infusion
- Allopurinol (Zyloprim) or Rasburicase (Elitek) recommended for tumor lysis syndrome prophylaxis
- PCP prophylaxis recommended
- Antiviral prophylaxis recommended
28-day cycle for 6 cycles
References
- GALTON: Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30;125(18):2779-85. Epub 2015 Mar 13. link to original article contains verified protocol link to PMC article PubMed
CFAR
back to top |
CFAR: Cyclophosphamide, Fludarabine, Alemtuzumab, Rituximab
Regimen
Study | Evidence | Efficacy |
---|---|---|
Parikh et al. 2011 | Phase II | ORR: 92% |
Note that the doses of cyclophosphamide and fludarabine are lower than in the r/r CFAR regimen.
Chemotherapy
- Cyclophosphamide (Cytoxan) 200 mg/m2 IV once per day on days 3 to 5
- Fludarabine (Fludara) 20 mg/m2 IV once per day on days 3 to 5
- Alemtuzumab (Campath) 30 mg IV once per day on days 1, 3, 5
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 2
- Cycles 2 to 6: 500 mg/m2 IV once on day 2
Supportive medications
- Pegfilgrastim (Neulasta) 6 mg SC once on day 6
- Acetaminophen (Tylenol) 500 mg PO once prior to each Rituximab (Rituxan)/Alemtuzumab (Campath)
- Diphenhydramine (Benadryl) 25 to 50 mg IV or PO once prior to each Rituximab (Rituxan)/Alemtuzumab (Campath)
- Hydrocortisone (Cortef) 100 mg IV once prior to each Rituximab (Rituxan)/Alemtuzumab (Campath)
- Allopurinol (Zyloprim) 300 mg PO once per day for at least days 1 to 7 of cycle 1
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO once per day during treatment and for at least 3 to 6 months after last course
- Antiviral prophylaxis with ONE of the following:
- Valacyclovir (Valtrex) 500 mg PO once per day during treatment and for at least 3 to 6 months after last course
- OR Valganciclovir (Valcyte) 450 mg PO twice per day during treatment and for at least 3 to 6 months after last course
28-day cycle for 6 cycles
References
- Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25;118(8):2062-8. Epub 2011 Jul 12. link to original article link to PMC article contains verified protocol PubMed
G-FC
back to top |
G-FC: Gazyva (Obinutuzumab), Fludarabine, Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Brown et al. 2015 (GALTON) | Non-randomized |
Chemotherapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 100 mg IV once on day 1, then 900 mg IV once on day 2, then 1000 mg IV once on days 8 & 15
- Cycles 2 to 6: 1000 mg IV once on day 1
- Fludarabine (Fludara) as follows:
- Cycle 1: 25 mg/m2 IV once per day on days 2 to 4
- Cycles 2 to 6: 25 mg/m2 IV once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) as follows:
- Cycle 1: 250 mg/m2 IV once per day on days 2 to 4
- Cycles 2 to 6: 250 mg/m2 IV once per day on days 1 to 3
Supportive medications
- Acetaminophen (Tylenol) (dose not specified) prior to each Obinutuzumab (Gazyva) infusion
- Antihistamine e.g. Diphenhydramine (Benadryl) prior to each Obinutuzumab (Gazyva) infusion
- Highly potent corticosteroid (e.g. Prednisolone (Millipred) 100 mg IV) before first Obinutuzumab (Gazyva) infusion
- Allopurinol (Zyloprim) or Rasburicase (Elitek) recommended for tumor lysis syndrome prophylaxis
- PCP prophylaxis recommended
- Antiviral prophylaxis recommended
28-day cycle for 6 cycles
References
- GALTON: Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30;125(18):2779-85. Epub 2015 Mar 13. link to original article contains verified protocol link to PMC article PubMed
HDMP-R
back to top |
HDMP-R: High Dose, MethylPrednisolone & Rituximab
Regimen
Study | Evidence |
---|---|
Castro et al. 2009 | Phase II |
Chemotherapy
- Methylprednisolone (Solumedrol) 1000 mg/m2 IV over 90 minutes once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 total divided over 2 days IV once on days 1 & 2, then 375 mg/m2 IV once per day on days 8, 15, 22
- Cycles 2 & 3: 375 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- Cimetidine (Tagamet) as premedication for Methylprednisolone (Solumedrol)
- Acetaminophen (Tylenol) as premedication for Rituximab (Rituxan)
- Diphenhydramine (Benadryl) as premedication for Rituximab (Rituxan)
- Trimethoprim/Sulfamethoxazole (Bactrim DS) (or equivalent) prophylaxis during therapy and continuing for 2 months after treatment is complete
- Acyclovir (Zovirax) (or equivalent) prophylaxis during therapy and continuing for 2 months after treatment is complete
- Fluconazole (Diflucan) (or equivalent) prophylaxis during therapy and continuing for 2 months after treatment is complete
- Allopurinol (Zyloprim) 300 mg PO once per day, started 3 days before the start of therapy and continued during treatment
- Patients with glucose greater than 200 on days of treatment received regular insulin SC sliding scale on days of treatment
28-day cycles for 3 cycles
References
- Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1779-89. Epub 2009 Aug 20. contains protocol link to PMC article PubMed
Idelalisib & Rituximab
back to top |
Regimen
Study | Evidence |
---|---|
O'Brien et al. 2015 (Study 101-08) | Phase II |
In a letter dated 3/21/2016, Gilead states that idelalisib should not be used for first line treatment of CLL.
Chemotherapy
- Idelalisib (Zydelig) 150 mg PO twice per day for 48 weeks
- Rituximab (Rituxan) 375 mg/m2 IV once per week for 8 weeks
48-week treatment; patients who had not progressed could continue on an extension study
References
- Study 101-08: O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686-94. Epub 2015 Oct 15. link to original article contains verified protocol link to PMC article PubMed
Lenalidomide & Rituximab
back to top |
Variant #1
Study | Evidence |
---|---|
James et al. 2014 (CRC014) | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) with escalation in the absence of grade 2 or higher toxicities as follows:
- Cycle 1: 2.5 mg PO once per day on days 1 to 7, then 5 mg PO once per day on days 8 to 21
- Cycle 2: 5 mg PO once per day on days 1 to 21
- Subsequent cycles: 10 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on days 31 & 33
- Cycle 2: 375 mg/m2 IV once per week on weeks 1 to 4
- Subsequent cycles: 375 mg/m2 IV once on day 1
Supportive medications
- Allopurinol (Zyloprim) prior to starting lenalidomide and with any dose escalation
- Aspirin 81 mg PO once per day
Cycle 1 is 35 days, then 28-day cycle up to 7 total cycles
Variant #2
Study | Evidence |
---|---|
Fowler et al. 2014 | Phase II |
This combination was only studied in SLL (as opposed to CLL). Lenalidomide is dose-escalated to avoid tumor flare.
Chemotherapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21, with an escalation of 5 mg/month to goal of 20 mg PO once per day
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for up to 12 cycles
References
- CRC014: James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the Chronic Lymphocytic Leukemia Research Consortium. J Clin Oncol. 2014 Jul 1;32(19):2067-73. Epub 2014 May 27. link to original article contains verified protocol link to PMC article PubMed
- Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. link to original article contains protocol link to PMC article PubMed
O-FC
back to top |
O-FC: Ofatumumab, Fludarabine, Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Wierda et al. 2011 (407 Study) | Phase II |
Chemotherapy
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1
- Cycles 2 to 6: 500 mg or 1000 mg IV once on day 1
- Fludarabine (Fludara) as follows:
- Cycle 1: 25 mg/m2 IV once per day on days 2 to 4
- Cycles 2 to 6: 25 mg/m2 IV once per day on days 1 to 3 (note: there was ambiguity in Wierda et al. 2011 about whether both fludarabine and cyclophosphamide are given three days per cycle, or whether fludarabine is given once per cycle and only cyclophosphamide is given three days per cycle)
- Cyclophosphamide (Cytoxan) as follows:
- Cycle 1: 250 mg/m2 IV once per day on days 2 to 4
- Cycle 2 to 6: 250 mg/m2 IV once per day on days 1 to 3
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO as premedication prior to Ofatumumab (Arzerra)
- Cetirizine (Zyrtec) 10 mg (or equivalent) PO as premedication prior to Ofatumumab (Arzerra)
- Prednisolone (Millipred) 100 mg (or equivalent) PO once before doses 1 & 2 of Ofatumumab (Arzerra), then reduced by physician discretion for later doses
- May be used at physician discretion:
- Allopurinol (Zyloprim) for tumor lysis syndrome prophylaxis
- Antiviral and PCP (Pneumocystis jiroveci pneumonia) prophylaxis
- Growth factor support
28-day cycle for 6 cycles
References
- Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16;117(24):6450-8. Epub 2011 Apr 15. link to original article contains verified protocol link to PMC article PubMed
PCO
back to top |
PCO: Pentostatin, Cyclophosphamide, Ofatumumab
Regimen
Study | Evidence |
---|---|
Shanafelt et al. 2013 | Phase II |
Tedeschi et al. 2015 | Phase II |
Strati et al. 2016 | Phase II |
Chemotherapy
- Pentostatin (Nipent) 2 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once on day 8
- Cycles 2 to 6: 1000 mg IV once on day 1
Supportive medications
- Best described in Shanafelt et al. 2013:
- Methylprednisolone (Solumedrol) 80 mg IV once prior to each dose of Ofatumumab (Arzerra)
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 14 of cycle 1
- Pegfilgrastim (Neulasta) 6 mg SC once on day 2
- Trimethoprim/Sulfamethoxazole (Bactrim DS) or similar for PJP prophylaxis for one year from start of treatment
- Valacyclovir (Valtrex) or similar for HSV prophylaxis for one year from start of treatment
21-day cycle for 6 cycles
Subsequent treatment
- Strati et al. 2016: Ofatumumab consolidation
References
- Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013 Nov 1;119(21):3788-96. Epub 2013 Aug 6. Erratum in: Cancer. 2014 Mar 15;120(6):926. Dosage error in article text. link to original article link to PMC article contains verified protocol PubMed
- Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda–CLL Workgroup. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. Haematologica. 2015 Dec;100(12):e501-4. Epub 2015 Aug 20. link to original article contains verified protocol link to PMC article PubMed
- Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Sep;3(9):e407-14. Epub 2016 Aug 1. link to original article contains protocol PubMed
PCR
back to top |
PCR: Pentostatin, Cyclophosphamide, Rituximab
Variant #1
Study | Evidence |
---|---|
Samaniego et al. 2015 | Phase II |
This regimen was specifically studied in SLL, not CLL.
Chemotherapy
- Pentostatin (Nipent) 4 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
Supportive medications
- Ondansetron (Zofran) 8 mg (route not specified) prior to chemotherapy
- Diphenhydramine (Benadryl) 25 mg (route not specified) prior to chemotherapy
- 500 ml of 5% dextrose/one-half normal saline before and after each Pentostatin (Nipent) dose
- Filgrastim (Neupogen) at the discretion of the treating physician
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 15 of cycle 1
- Trimethoprim/Sulfamethoxazole (Bactrim DS) once per day three days per week during and for 1 month following therapy
- Acyclovir (Zovirax) 400 mg PO twice per day during and for 1 month following therapy
21-day cycle for 6 cycles
Variant #2
Study | Evidence |
---|---|
Kay et al. 2007 | Phase II |
Shanafelt et al. 2007 | Phase II |
Chemotherapy
- Pentostatin (Nipent) 2 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Rituximab (Rituxan) as follows:
- Cycle 1: 100 mg/m2 IV once on day 1, then 375 mg/m2 IV once per day on days 3 & 5
- Cycles 2 to 6: 375 mg/m2 IV once on day 1
Supportive medications
- Note: see references for details, as they differ by paper.
- Filgrastim (Neupogen) once per day, starting on day 3 for up to 10 days or until ANC greater than 1000/uL for 2 straight days
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 15 of cycle 1
- Prophylactic Trimethoprim/Sulfamethoxazole (Bactrim DS) for 1 year
- Prophylactic Acyclovir (Zovirax) for 1 year
28-day cycle for 6 cycles
References
- Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007 Jan 15;109(2):405-11. Epub 2006 Sep 28. link to original article contains protocol link to PMC article PubMed
- Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007 Jun 1;109(11):2291-8. link to original article PubMed
- Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun;169(6):814-23. Epub 2015 Mar 31. link to original article contains verified protocol link to PMC article PubMed
Rituximab monotherapy
back to top |
Variant #1
Study | Evidence |
---|---|
Williams et al. 2016 (RESORT) | Non-randomized portion of RCT |
This regimen was intended for patients with SLL.
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once per week; initial infusion rate of 50 mg/H, then increased as tolerated by 50 mg/H every 30 minutes, to a maximum rate of 300 mg/H
Supportive medications
- Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to each dose of Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 50 mg PO 30 minutes prior to each dose of Rituximab (Rituxan)
4-week course
Patients with PR/CR were randomized to indefinite rituximab versus salvage rituximab at time of progression.
Variant #2
Study | Evidence |
---|---|
Hainsworth et al. 2003 | Phase II |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Optional alternate initial dosing for patients with WBC count greater than 100 x 109/L: 100 mg IV once on day 1, with remainder of the 375 mg/m2 dosage given on day 2
- Initial infusion rate with first dose of rituximab: 50 mg/hr, then increased as tolerated by 50 mg/hr every 30 minutes to a maximum of 400 mg/hr. Infusion rate with subsequent doses of rituximab (if first dose tolerated): 100 mg/hr, then increased as tolerated by 100 mg/hr every 30 minutes to a maximum of 400 mg/hr.
Supportive medications
- If WBC count greater than 50 x 109/L or massive lymphadenopathy: Allopurinol (Zyloprim) 300 mg PO once per day, starting 3 days before the first dose of Rituximab (Rituxan)
- Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 50 mg IV once 30 minutes prior to Rituximab (Rituxan)
- One of the following, 30 minutes prior to Rituximab (Rituxan):
- Cimetidine (Tagamet) 300 mg IV once
- Ranitidine (Zantac) 50 mg IV once
28-day cycle for 6 cycles
Patients with response or stable disease then received maintenance rituximab.
References
- Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003 May 1;21(9):1746-51. link to original article PubMed
- Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. link to original article contains protocol link to PMC article PubMed
Ruxolitinib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Jain et al. 2017 | Phase II |
Note: this was a trial focused on symptom control, not efficacy.
Chemotherapy
- Ruxolitinib (Jakafi) 10 mg PO twice per day
References
- Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb;4(2):e67-e74. Epub 2017 Jan 11. link to original article contains protocol link to PMC article PubMed
Consolidation and/or maintenance after first-line therapy
Alemtuzumab monotherapy
back to top |
Variant #1, 6-week course
Study | Evidence |
---|---|
Varghese et al. 2017 (NCRN CLL 207) | Phase II |
Preceding treatment
- Chemotherapy (details not specified)
Chemotherapy
- Alemtuzumab (Campath) 30 mg SC 3 times per week
6-week course
Variant #2, 12-week course
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Wendtner et al. 2004 (GCLLSG CLL4B) | Phase III (E) | Observation | Superior PFS (*) |
Note: this study closed early due to high rates of infections in the experimental arm; efficacy is based on the 2009 update.
Preceding treatment
Chemotherapy
- Alemtuzumab (Campath) as follows:
- Day 1: 3 mg SC once
- Day 2, if 3 mg dose is well tolerated: 10 mg SC once
- Day 3 onwards, if 10 mg dose is well tolerated: 30 mg SC once on day 3, then SC 3 times per week
12-week course
References
- GCLLSG CLL4B: Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004 Jun;18(6):1093-101. link to original article contains verified protocol PubMed
- Update: Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8. Epub 2008 Oct 30. link to original article PubMed
- NCRN CLL207: Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, Dearden C, Fegan C, Milligan D, Smith AF, Gregory W, Hillmen P; NCRI CLL Sub-Group. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. Br J Haematol. 2017 Feb;176(4):573-582. Epub 2016 Dec 29. link to original article contains protocol PubMed
Lenalidomide monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Fink et al. 2017 (GCLLSG CLLM1) | Phase III (E) | Observation | Superior PFS |
Note that while the NCT record reports dose increases beyond 15 mg PO once per day, the abstract states that 15 mg PO once per day was the "target dose".
Preceding treatment
- GCLLSG CLLM1: "Chemoimmunotherapy"
Chemotherapy
- Lenalidomide (Revlimid) as follows:
- Cycle 1: 5 mg PO once per day
- If tolerated, Cycles 2 to 6: 10 mg PO once per day
- If tolerated, Cycle 7 onwards: 15 mg PO once per day
28-day cycles
References
- GCLLSG CLLM1: Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486. Epub 2017 Sep 12. link to original article contains protocol PubMed
Observation
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Wendtner et al. 2004 (GCLLSG CLL4B) | Phase III (C) | Alemtuzumab | Inferior PFS (*) |
Hochster et al. 2009 (ECOG E1496) | Phase III (C) | Rituximab | Inferior PFS |
Michallet et al. 2010 | Phase III (C) | Autologous HSCT | Inferior EFS |
Sutton et al. 2011 (Auto-LLC 2001) | Phase III (C) | Autologous HSCT | Inferior EFS |
Foà et al. 2014 (ML21445) | Phase III (C) | Rituximab | Might have inferior PFS |
Greil et al. 2016 (AGMT CLL-8a) | Phase III (C) | Rituximab | Inferior PFS |
Fink et al. 2017 (GCLLSG CLLM1) | Phase III (C) | Lenalidomide | Inferior PFS |
Dartigeas et al. 2017 (CLL 2007 SA) | Phase III (C) | Rituximab | Inferior PFS |
No further treatment; used as a comparator arm. GCLLSG CLL4B closed early due to high rates of infections in the experimental arm; efficacy is based on the 2009 update.
Preceding treatment
- GCLLSG CLL4B: F x 6 versus FC x 6
- ECOG E1496: CVP
- Auto-LLC 2001: mini-CHOP x 3, then F x 3
- ML21445: Clb-R
- AGMT CLL-8a: "Rituximab-containing chemoimmunotherapy"
- GCLLSG CLLM1: "Chemoimmunotherapy"
- CLL 2007 SA: FCR x 4
References
- GCLLSG CLL4B: Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004 Jun;18(6):1093-101. link to original article PubMed
- Update: Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8. Epub 2008 Oct 30. link to original article PubMed
- ECOG E1496: Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1;27(10):1607-14. Epub 2009 Mar 2. link to original article contains verified protocol link to PMC article PubMed
- Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D; EBMT Chronic Leukemia Working Party. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011 Feb 3;117(5):1516-21. Epub 2010 Nov 24. link to original article PubMed
- Auto-LLC 2001: Sutton L, Chevret S, Tournilhac O, Diviné M, Leblond V, Corront B, Leprêtre S, Eghbali H, Van Den Neste E, Michallet M, Maloisel F, Bouabdallah K, Decaudin D, Berthou C, Brice P, Gonzalez H, Chapiro E, Radford-Weiss I, Leporrier N, Maloum K, Nguyen-Khac F, Davi F, Lejeune J, Merle-Béral H, Leporrier M; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC). Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011 Jun 9;117(23):6109-19. Epub 2011 Mar 15. link to original article PubMed
- ML21445: Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014 May;89(5):480-6. Epub 2014 Feb 18. link to original article contains verified protocol PubMed
- AGMT CLL-8a: Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. link to original article contains protocol PubMed
- GCLLSG CLLM1: Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486. Epub 2017 Sep 12. link to original article contains protocol PubMed
- CLL 2007 SA: Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018 Feb;5(2):e82-e94. Epub 2017 Dec 20. link to original article contains protocol PubMed
Ofatumumab monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Strati et al. 2016 | Phase II |
Preceding treatment
- PCO x 6
Chemotherapy
- Ofatumumab (Arzerra) 1000 mg IV once on day 1
28-day cycle for 6 cycles
References
- Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Sep;3(9):e407-14. Epub 2016 Aug 1. link to original article contains protocol PubMed
Rituximab monotherapy
back to top |
Variant #1, 1 year
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Foà et al. 2014 (ML21445) | Phase III (E) | Observation | Might have superior PFS |
Preceding treatment
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once every 8 weeks
12 doses total
Variant #2, 2 years, given q3mo
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Bosch et al. 2009 | Phase II | ||
Greil et al. 2016 (AGMT CLL-8a) | Phase III (E) | Observation | Superior PFS |
Preceding treatment
- Bosch et al. 2009: R-FCM
- AGMT CLL-8a: "Rituximab-containing chemoimmunotherapy"
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once every 3 months
2 years total (8 doses)
Variant #3, 2 years, given q8wk
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Dartigeas et al. 2017 (CLL 2007 SA) | Phase III (E) | Observation | Superior PFS |
Note the higher dose used here.
Preceding treatment
- FCR x 4
Chemotherapy
- Rituximab (Rituxan) 500 mg/m2 IV once on day 1
8-week cycle for up to 2 years
Variant #4, 2 years, given q6mo
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Hainsworth et al. 2003 | Phase II | ||
Hochster et al. 2009 (ECOG E1496) | Phase III (E) | Observation | Superior PFS |
ECOG E1496 included patients with SLL, but they were grouped into an "other" non-follicular lymphoma category.
Preceding treatment
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
Supportive medications
- Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 50 mg IV once 30 minutes prior to Rituximab (Rituxan)
- One of the following, 30 minutes prior to Rituximab (Rituxan):
- Cimetidine (Tagamet) 300 mg IV once
- Ranitidine (Zantac) 50 mg IV once
One course every 6 months (16 total doses)
Variant #5, indefinite 375 mg/m2 q3mo
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Williams et al. 2016 (RESORT) | Phase III (C) | Salvage rituximab | Seems to have superior TTTF |
Intended for patients with SLL.
Preceding treatment
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once every 13 weeks
Continued until treatment failure
Variant #6, indefinite 500 mg/m2 q3mo
Study | Evidence |
---|---|
Foon et al. 2009 | Phase II |
Preceding treatment
- FCR-Lite x 6
Chemotherapy
- Rituximab (Rituxan) 500 mg/m2 IV once every 3 months
Continued until relapse
References
- Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003 May 1;21(9):1746-51. link to original article PubMed
- Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Feb 1;27(4):498-503. Epub 2008 Dec 15. link to original article contains verified protocol PubMed
- Update: Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012 Mar 29;119(13):3184-5. link to original article PubMed
- ECOG E1496: Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1;27(10):1607-14. Epub 2009 Mar 2. link to original article contains verified protocol link to PMC article PubMed
- Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84. Epub 2009 Aug 24. link to original article contains verified protocol PubMed
- Update: Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013 Dec 5;122(24):3951-9. Epub 2013 Oct 11. link to original article contains verified protocol PubMed
- ML21445: Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014 May;89(5):480-6. Epub 2014 Feb 18. link to original article contains verified protocol PubMed
- ECOG E4402: Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. link to original article contains protocol link to PMC article PubMed
- AGMT CLL-8a: Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. link to original article contains protocol PubMed
- CLL 2007 SA: Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018 Feb;5(2):e82-e94. Epub 2017 Dec 20. link to original article contains protocol PubMed
- PALG CLL4: Robak T, Błoński J, Skotnicki AB, Piotrowska M, Wróbel T, Rybka J, Kłoczko J, Bołkun Ł, Budziszewska BK, Walczak U, Uss A, Fidecka M, Smolewski P. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. Eur J Haematol. 2018 May;100(5):465-474. Epub 2018 Mar 22. link to original article PubMed
Relapsed or refractory, randomized data
Bendamustine monotherapy
back to top |
Variant #1, 70 mg/m2
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Robak et al. 2016 | Randomized Phase II (C) | Bendamustine & Otlertuzumab | Seems to have inferior PFS |
Chemotherapy
- Bendamustine 70 mg/m2 IV over 30 minutes once per day on days 1 & 2
28-day cycle for 6 cycles
Variant #2, 100 mg/m2
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Niederle et al. 2013 | Phase III (E) | Fludarabine | Seems non-inferior |
Chemotherapy
- Bendamustine 100 mg/m2 IV once per day on days 1 & 2
28-day cycle for up to 8 cycles
Variant #3, 120 mg/m2
Study | Evidence |
---|---|
Friedberg et al. 2008 | Phase II |
Kahl et al. 2010 | Phase II |
Chemotherapy
- Bendamustine 120 mg/m2 IV once per day on days 1 & 2
21-day cycle for 6 to 8 (Kahl et al. 2010) or up to 12 (Friedberg et al. 2008) cycles
References
- Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008 Jan 10;26(2):204-10. Erratum in: J Clin Oncol. 2008 Apr 10;26(11) 1911. link to original article contains verified protocol PubMed
- Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106-14. link to original article contains verified protocol link to PMC article PubMed
- Retrospective: Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. link to PMC article PubMed
- Niederle N, Megdenberg D, Balleisen L, Heit W, Knauf W, Weiß J, Freier W, Hinke A, Ibach S, Eimermacher H. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013 May;92(5):653-60. Epub 2013 Jan 23. link to original article contains verified protocol PubMed
- Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017 Feb;176(4):618-628. Epub 2016 Dec 15. link to original article contains verified protocol link to PMC article PubMed
BR
back to top |
BR: Bendamustine & Rituximab
R-B: Rituximab & Bendamustine
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Fischer et al. 2011 | Phase II | ||
Chanan-Khan et al. 2015 (HELIOS) | Phase III (C) | BR & Ibrutinib | Inferior PFS |
Zelenetz et al. 2017 (Tugela) | Phase III (C) | BR & Idelalisib | Inferior PFS |
Michallet et al. 2018 (MABLE) | Phase III (E) | R-Clb | Superior CR rate |
Seymour et al. 2018 (MURANO) | Phase III (C) | Venetoclax & Rituximab | Inferior OS |
Chemotherapy
- Bendamustine 70 mg/m2 IV once per day on days 1 & 2
- HELIOS gave 1st cycle on days 2 & 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 0
- HELIOS gave on day 1
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
- Cycle 1: 375 mg/m2 IV once on day 0
28-day cycle for up to 6 cycles based on response and toxicity
References
- Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011 Sep 10;29(26):3559-66. Epub 2011 Aug 15. link to original article contains protocol PubMed
- Retrospective: Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013 Jun;4(3):157-71. link to PMC article PubMed
- HELIOS: Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11. Epub 2015 Dec 5. link to original article contains protocol PubMed
- Tugela: Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28. link to original article link to PMC article contains protocol PubMed
- MABLE: Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1. link to original article contains verified protocol link to PMC article PubMed
- MURANO: Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107-1120. link to original article contains verified protocol PubMed
- Update: Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2018 Dec 3. [Epub ahead of print] link to original article PubMed
BR & Ibrutinib
back to top |
BR & Ibrutinib: Bendamustine, Rituximab, Ibrutinib
IBR: Ibrutinib, Bendamustine, Rituximab
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Brown et al. 2015 (PCYC-1108) | Phase II | ||
Chanan-Khan et al. 2015 (HELIOS) | Phase III (E) | BR | Superior PFS |
PCYC-1108 also evaluated FCR-ibrutinib (non-randomized) but accrual to that arm was extremely low and it was prematurely discontinued.
Chemotherapy
- Bendamustine 70 mg/m2 IV once per day on days 1 & 2
- HELIOS gave 1st cycle on days 2 & 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1 or split between days 1 & 2 (option described in PCYC-1108)
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
- Ibrutinib (Imbruvica) 420 mg PO once per day
28-day cycle for up to 6 cycles (BR) and indefinitely (ibrutinib)
References
- PCYC-1108: Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 7;125(19):2915-22. Epub 2015 Mar 9. link to original article contains verified protocol link to PMC article PubMed
- HELIOS: Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11. Epub 2015 Dec 5. link to original article contains protocol PubMed
BR & Idelalisib
back to top |
BR & Idelalisib: Bendamustine, Rituximab, Idelalisib
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Zelenetz et al. 2017 (Tugela) | Phase III (E) | BR | Superior PFS |
Chemotherapy
- Bendamustine as follows:
- Cycles 1 to 6: 70 mg/m2 IV once per day on days 1 & 2
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 0
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
- Idelalisib (Zydelig) 150 mg PO twice per day
28-day cycles
References
- Tugela: Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28. link to original article contains protocol link to PMC article PubMed
Duvelisib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Flinn et al. 2018 (DUO) | Phase III (E) | Ofatumumab | Superior PFS |
Chemotherapy
- Duvelisib (Copiktra) 25 mg PO twice per day
Given for up to 18 cycles, progression of disease, or unacceptable toxicity
References
- Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 Dec 6;132(23):2446-2455. link to original article contains verified protocol PubMed
FCR
back to top |
FCR: Fludarabine, Cyclophosphamide, Rituximab
R-FC: Rituximab, Fludarabine, Cyclophosphamide
Variant #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Awan et al. 2014 (LUCID) | Phase III (C) | Lumiliximab + FCR | Seems not superior |
Chemotherapy
- Fludarabine (Fludara) as follows:
- Cycle 1: 25 mg/m2 IV over at least 10 to 30 minutes once per day on days 2 to 4
- Cycles 2 to 6: 25 mg/m2 IV over at least 10 to 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) as follows:
- Cycle 1: 250 mg/m2 IV over at least 10 to 30 minutes once per day on days 2 to 4
- Cycles 2 to 6: 250 mg/m2 IV over at least 10 to 30 minutes once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 50 mg/m2 IV over 4 hours once on day 1, then 450 mg/m2 IV once on day 3
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
Supportive medications
- Cotrimoxazole or an equivalent
- Acyclovir (Zovirax) 400 mg PO twice per day or an equivalent
28-day cycle for 6 cycles
Variant #2
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Robak et al. 2010 (REACH) | Phase III (E) | FC | Superior PFS |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 250 mg/m2 IV once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
Supportive medications
- Note: varied according to reference.
- Diphenhydramine (Benadryl) 25 mg IV once 30 minutes prior to Rituximab (Rituxan)
- Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to Rituximab (Rituxan)
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 7 of cycle 1
- Some patients received:
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO twice per week
- Valacyclovir (Valtrex) 500 mg PO once per day
28-day cycle for 6 cycles
Variant #3
Study | Evidence |
---|---|
Wierda et al. 2005 | Phase II |
Chemotherapy
- Fludarabine (Fludara) as follows:
- Cycle 1: 25 mg/m2 IV once per day on days 2 to 4
- Cycles 2 to 6: 25 mg/m2 IV once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) as follows:
- Cycle 1: 250 mg/m2 IV once per day on days 2 to 4
- Cycles 2 to 6: 250 mg/m2 IV once per day on days 1 to 3
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1
- Cycles 2 to 6: 500 mg/m2 IV once on day 1
Supportive medications
- Diphenhydramine (Benadryl) 25 to 50 mg PO once prior to Rituximab (Rituxan)
- Acetaminophen (Tylenol) 650 mg PO once prior to Rituximab (Rituxan)
- Ondansetron (Zofran) 24 mg IV once prior to chemotherapy
28-day cycle for up to 6 cycles
Variant #4
Study | Evidence |
---|---|
Tam et al. 2006 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV over 15 to 30 minutes once per day on days 1 to 3
- Cyclophosphamide (Cytoxan) 250 mg/m2 IV over 15 to 30 minutes once per day on days 1 to 3
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
28-day cycle for up to 6 cycles or "attainment of maximum response"
References
- Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8. Epub 2005 Mar 14. link to original article contains verified protocol PubMed
- Update: Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Mar 17;117(11):3016-24. Epub 2011 Jan 18. link to original article link to PMC article PubMed
- Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 2006 Jun 1;106(11):2412-20. link to original article contains verified protocol PubMed
- REACH: Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1756-65. Epub 2010 Mar 1. link to original article contains protocol PubMed content property of HemOnc.org
- LUCID: Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov;167(4):466-77. Epub 2014 Aug 8. link to original article contains verified protocol PubMed
Fludarabine monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Johnson et al. 1996 | Phase III (E) | CAP | Seems not superior |
Niederle et al. 2013 | Phase III (C) | Bendamustine | Seems non-inferior |
Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.
Chemotherapy
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 1 to 5
28-day cycle for up to 6 to 12 cycles
References
- Johnson S, Smith AG, Löffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W; The French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet. 1996 May 25;347(9013):1432-8. link to original article contains protocol PubMed
- Niederle N, Megdenberg D, Balleisen L, Heit W, Knauf W, Weiß J, Freier W, Hinke A, Ibach S, Eimermacher H. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013 May;92(5):653-60. Epub 2013 Jan 23. link to original article contains verified protocol PubMed
Ibrutinib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Byrd et al. 2013 (PCYC-1102) | Phase II | ||
Byrd et al. 2014 (RESONATE) | Phase III (E) | Ofatumumab | Superior OS |
Farooqui et al. 2014 (NHLBI 12-H-0035) | Phase II, <20 pts | ||
O'Brien et al. 2016 (RESONATE-17) | Phase II | ||
Sharman et al. 2017 (GENUINE) | Phase III (C) | Ibrutinib & Ublituximab | Inferior ORR |
Both 420 mg and 840 mg doses were investigated in PCYC-1102: "the similar response in the two dose groups provide support for the use of the 420-mg dose of ibrutinib for relapsed CLL." The others used the 420 mg dose. RESONATE-17 was intended for patients with 17p deletion.
Chemotherapy
- Ibrutinib (Imbruvica) 420 mg PO once per day
Given indefinitely
References
- PCYC-1102: Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32-42. link to original article contains verified protocol link to PMC article PubMed
- Update: Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16;125(16):2497-506. Epub 2015 Feb 19. link to original article link to PMC article PubMed
- Update: O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 Apr 26;131(17):1910-1919. Epub 2018 Feb 2. link to original article PubMed
- RESONATE: Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; the RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. Epub 2014 May 31. link to original article contains verified protocol link to PMC article PubMed
- Update: Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 Jan;32(1):83-91. Epub 2017 Jun 8. link to original article PubMed
- NHLBI 12-H-0035: Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015 Feb;16(2):169-76. Epub 2014 Dec 31. link to original article contains protocol link to PMC article PubMed
- RESONATE-17: O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. Epub 2016 Sep 13. link to original article contains protocol PubMed
- Retrospective: Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 Dec 22;128(25):2899-2908. link to original article link to PMC article PubMed
- Abstract: Jeff Porter Sharman, Danielle M. Brander, Anthony R. Mato, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder, Scott D. Lunin, Nilanjan Ghosh, Alexander Zweibach, Mikhail Shtivelband, Patrick M. Travis, Jason Claud Chandler, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, and Ian Flinn. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study. Journal of Clinical Oncology 2017 35:15_suppl, 7504-7504 link to abstract
Idelalisib & Ofatumumab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Jones et al. 2017 (GS-US-312-0119) | Phase III (E) | Ofatumumab | Superior PFS |
Chemotherapy
- Idelalisib (Zydelig) 150 mg PO twice per day
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
- Cycle 2: 1000 mg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 1000 mg IV once on day 1
28-day cycle for 6 cycles
References
- GS-US-312-0119: Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114-e126. link to original article contains protocol PubMed
Idelalisib & Rituximab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Furman et al. 2014 (Study 116) | Phase III (E) | Rituximab | Seems to have superior OS |
Chemotherapy
- Idelalisib (Zydelig) 150 mg PO twice per day
- Rituximab (Rituxan) as follows:
- Week 1: 375 mg/m2 IV once
- Weeks 3 to 9: 500 mg/m2 IV once every two weeks
- Weeks 13 to 21: 500 mg/m2 IV once every four weeks
Rituximab is given for 8 total doses; idelalisib continues until progression, and can be increased to 300 mg PO twice per day at that point
References
- Study 116: Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. Epub 2014 Jan 22. link to original article contains verified protocol link to PMC article PubMed
Ofatumumab monotherapy
back to top |
Variant #1, 2 cycles
Study | Evidence |
---|---|
Österborg et al. 2015 (GEN416) | Phase II |
Patients in this trial were fludarabine refractory and had previously received ofatumumab; this is a re-treatment trial.
Chemotherapy
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22
- Cycle 2: 2000 mg IV once per day on days 1, 8, 15, 22
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO once prior to each infusion
- Cetirizine (Zyrtec) (or equivalent) 10 mg PO once prior to each infusion
- Prednisolone (Millipred) 100 mg (or equivalent) PO once before infusions 1, 2, and 9 (question whether this was a typo), reduced or omitted if initial infusions well-tolerated
28-day cycle for 2 cycles
Subsequent treatment
- Patients with SD or better could proceed to ofatumumab maintenance
Variant #2, 6 cycles
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Coiffier et al. 2007 | Phase I/II | ||
Wierda et al. 2010 (Hx-CD20-406) | Phase II | ||
Byrd et al. 2014 (RESONATE) | Phase III (C) | Ibrutinib | Inferior OS |
Jones et al. 2017 (GS-US-312-0119) | Phase III (C) | Idelalisib & Ofatumumab | Inferior PFS |
(DUO) | Phase III (C) | Duvelisib | See note |
Note: this regimen is sometimes described as 300 mg IV once on day 1, then 2000 mg IV once per week for 7 weeks, then 2000 mg IV once every 4 weeks for 16 weeks. We are not aware of any published results for DUO; we will add them when available. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22
- Cycle 2: 2000 mg IV once per day on days 1, 8, 15, 22
- Cycles 3 to 6: 2000 mg IV once on day 1
Supportive medications
- Prednisolone (Millipred) 100 mg (or equivalent) PO once before infusions 1, 2, and 9 (question whether this was a typo), reduced to lower doses if initial infusions well-tolerated
28-day cycle for 6 cycles
Variant #3, 12 cycles
Study | Evidence | Comparator |
---|---|---|
Ghia et al. 2017 (P07714) | Phase III (C) | Dinaciclib |
Note: this trial was terminated early and no statistical tests were performed; note also that cycle 3 is "skipped".
Chemotherapy
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22
- Cycle 2: 2000 mg IV once per day on days 1, 8, 15, 22
- Cycle 3: no treatment
- Cycles 4 to 12: 2000 mg IV once on day 1
28-day cycle for 12 cycles
References
- Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008 Feb 1;111(3):1094-100. Epub 2007 Nov 14. link to original article PubMed
- Hx-CD20-406: Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749-55. Epub 2010 Mar 1. link to original article contains protocol link to PMC article PubMed
- Subgroup analysis: Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011 Nov 10;118(19):5126-9. Epub 2011 Aug 19. link to original article link to PMC article PubMed
- Update: Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG; Hx-CD20-406 Study Investigators. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug;100(8):e311-4. Epub 2015 Mar 13. link to original article link to PMC article PubMed
- RESONATE: Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; the RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. Epub 2014 May 31. link to original article contains verified protocol link to PMC article PubMed
- Update: Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 Jan;32(1):83-91. Epub 2017 Jun 8. link to original article PubMed
- Retrospective: Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015 Apr;100(4):511-6. Epub 2015 Jan 16. link to original article link to PMC article PubMed
- GEN416: Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2015 Jul;170(1):40-9. Epub 2015 Mar 30. link to original article contains verified protocol PubMed
- GS-US-312-0119: Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114-e126. link to original article contains protocol PubMed
- P07714: Ghia P, Scarfò L, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C, Patton N. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2017 Mar 30;129(13):1876-1878. Epub 2017 Jan 26. link to original article PubMed
- DUO: CT.gov record
O-FC
back to top |
O-FC: Ofatumumab, Fludarabine, Cyclophosphamide
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Robak et al. 2016 (COMPLEMENT 2) | Phase III (E) | FC | Superior PFS |
Note: dosing details were not available in the abstract; this is the dosing from Wierda et al. 2011.
Chemotherapy
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1
- Cycles 2 to 6: 500 mg or 1000 mg IV once on day 1
- Fludarabine (Fludara) as follows:
- Cycle 1: 25 mg/m2 IV once per day on days 2 to 4
- Cycles 2 to 6: 25 mg/m2 IV once per day on days 1 to 3 (note: there was ambiguity in Wierda et al. 2011 about whether both fludarabine and cyclophosphamide are given three days per cycle, or whether fludarabine is given once per cycle and only cyclophosphamide is given three days per cycle)
- Cyclophosphamide (Cytoxan) as follows:
- Cycle 1: 250 mg/m2 IV once per day on days 2 to 4
- Cycle 2 to 6: 250 mg/m2 IV once per day on days 1 to 3
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO as premedication prior to Ofatumumab (Arzerra)
- Cetirizine (Zyrtec) 10 mg (or equivalent) PO as premedication prior to Ofatumumab (Arzerra)
- Prednisolone (Millipred) 100 mg (or equivalent) PO once before doses 1 & 2 of Ofatumumab (Arzerra), then reduced by physician discretion for later doses
- May be used at physician discretion:
- Allopurinol (Zyloprim) for tumor lysis syndrome prophylaxis
- Antiviral and PCP (Pneumocystis jiroveci pneumonia) prophylaxis
- Growth factor support
28-day cycle for 6 cycles
References
- Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, Homenda W, Błoński JZ, McKeown A, Gorczyca MM, Carey JL, Chang CN, Lisby S, Gupta IV, Grosicki S. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017 May;58(5):1084-1093. Epub 2016 Oct 12. link to original article PubMed
Rituximab monotherapy
back to top |
Variant #1, 4-week course
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
McLaughlin et al. 1998 | Phase II | ||
Williams et al. 2016 (RESORT) | Phase III (E) | Maintenance rituximab | Seems to have inferior TTTF |
Treatment in RESORT was preceded by rituximab and is given at time of progression.
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
One course
Variant #2, 8 doses
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Furman et al. 2014 (Study 116) | Phase III (C) | Idelalisib & Rituximab | Seems to have inferior OS |
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once on first dose, then 500 mg/m2 IV once on subsequent doses
Given every two weeks for 5 doses then every three weeks for 3 doses for 8 total doses.
References
- McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. link to original article contains verified protocol PubMed
- Study 116: Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. Epub 2014 Jan 22. link to original article contains verified protocol link to PMC article PubMed
- RESORT: Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75. Epub 2016 Mar 11. link to original article contains protocol link to PMC article PubMed
Venetoclax & Rituximab
back to top |
VEN+R: VENetoclax & Rituximab
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Seymour et al. 2018 (MURANO) | Phase III (E) | BR | Superior OS |
Chemotherapy
- Venetoclax (Venclexta) as follows:
- Week 1: 20 mg PO once per day
- Week 2: 50 mg PO once per day
- Week 3: 100 mg PO once per day
- Week 4: 200 mg PO once per day
- Week 5 onwards: 400 mg PO once per day
- Rituximab (Rituxan) as follows:
- Week 6: 375 mg/m2 IV once on day 1
- Weeks 10, 14, 18, 22, 26: 500 mg/m2 IV once on day 1
Up to 2-year course
References
- MURANO: Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107-1120. link to original article contains verified protocol PubMed
- Update: Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2018 Dec 3. [Epub ahead of print] link to original article PubMed
Relapsed or refractory, non-randomized or retrospective data
Acalabrutinib monotherapy
back to top |
Regimen
Study | Evidence | Efficacy |
---|---|---|
Byrd et al. 2015 (ACE-CL-001) | Phase I/II | ORR: 95% |
Note: this is the dose used in the expansion cohort.
Chemotherapy
- Acalabrutinib (Calquence) 100 mg PO twice per day
Continued until progression or intolerance
References
- ACE-CL-001: Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):323-32. Epub 2015 Dec 7. link to original article link to PMC article contains verified protocol PubMed
Alemtuzumab monotherapy
back to top |
Variant #1
Study | Evidence |
---|---|
Keating et al. 2002 | Phase II |
Rai et al. 2002 | Phase II |
Chemotherapy
- Alemtuzumab (Campath) as follows:
- 3 mg IV once per day, then increased as tolerated in terms of infusion reactions to 10 mg IV once per day, and then to 30 mg IV once per day
- Once 30 mg dose is tolerated: 30 mg IV over 2 hours, 3 times per week
Supportive medications
- Note: see references for details, as they differ by paper.
- Diphenhydramine (Benadryl) 50 mg PO once 30 minutes prior to Alemtuzumab (Campath)
- Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to Alemtuzumab (Campath)
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO 3 times per week, starting on day 8, continuing at a minimum until 2 months after treatment is complete
- Famciclovir (Famvir) 250 mg PO twice per day, starting on day 8, continuing at a minimum until 2 months after treatment is complete
Up to 12 to 16 weeks of therapy; total course varies depending on reference
Variant #2
Study | Evidence |
---|---|
Lozanski et al. 2004 | Phase II |
Chemotherapy
- Alemtuzumab (Campath) 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3, then 30 mg IV 3 days per week
Supportive medications
- G-CSF or GM-CSF per institutional protocol
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO 3 times per week during therapy and continued for 6 months after treatment is complete
- Acyclovir (Zovirax) 800 mg PO three times per day during therapy and continued for 6 months after treatment is complete; similar medication can be used if intolerant of acyclovir
12 weeks of therapy
References
- Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61. link to original article contains protocol PubMed
- Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002 Sep 15;20(18):3891-7. link to original article contains protocol PubMed
- Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004 May 1;103(9):3278-81. Epub 2004 Jan 15. link to original article contains protocol PubMed
Alemtuzumab & Rituximab
back to top |
Regimen
Study | Evidence |
---|---|
Faderl et al. 2003 | Phase II |
Chemotherapy
- Alemtuzumab (Campath) 3 mg IV once on day 1, 10 mg IV once on day 2, 30 mg IV once on day 3 of week 1, then 30 mg IV once per day on days 10, 12, 17, 19, 24, 26 (i.e. days 3 and 5 of weeks 2 to 4)
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
- For patients with WBC count greater than 50 x 109/L, the first dose of Rituximab (Rituxan) was split into 100 mg/m2 IV once on day 1 and 275 mg/m2 IV once on day 2
Supportive medications
- Prophylactic Trimethoprim/Sulfamethoxazole (Bactrim DS), given during therapy and continuing at a minimum until 2 months after treatment is complete
- Prophylactic Valacyclovir (Valtrex) (or equivalent), given during therapy and continuing at a minimum until 2 months after treatment is complete
28-day cycle for 1 to 2 cycles depending on response and toxicity
References
- Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 1;101(9):3413-5. Epub 2003 Jan 9. link to original article contains protocol Pubmed
Bendamustine & Ofatumumab
back to top |
BendOfa: Bendamustine & Ofatumumab
Regimen
Study | Evidence | Efficacy |
---|---|---|
Cortelezzi et al. 2013 (GIMEMA CLL0809) | Phase II | ORR: 72% (95% CI, 57–84%) |
Chemotherapy
- Bendamustine 70 mg/m2 IV once per day on days 1 & 2
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once on day 7
- Cycle 2 onwards: 1000 mg IV once on day 1
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO prior to Ofatumumab (Arzerra)
- Diphenhydramine (Benadryl) 50 mg PO prior to Ofatumumab (Arzerra)
- Methylprednisolone (Solumedrol) 40 mg IV prior to Ofatumumab (Arzerra)
- Allopurinol (Zyloprim) or Rasburicase (Elitek) required for prophylaxis against TLS; dose not specified
- Trimethoprim/Sulfamethoxazole (Bactrim DS) required; dose not specified
- Acyclovir (Zovirax) required; dose not specified
28-day cycle up to 6 cycles
References
- GIMEMA CLL0809: Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial. Leukemia. 2014 Mar;28(3):642-8. Epub 2013 Nov 13. link to original article contains verified protocol PubMed
CFAR
back to top |
CFAR: Cyclophosphamide, Fludarabine, Alemtuzumab, Rituximab
Regimen
Study | Evidence | Efficacy |
---|---|---|
Badoux et al. 2011 | Phase II | ORR: 65% |
Chemotherapy
- Cyclophosphamide (Cytoxan) 250 mg/m2 IV once per day on days 3 to 5
- Fludarabine (Fludara) 25 mg/m2 IV once per day on days 3 to 5
- Alemtuzumab (Campath) 30 mg IV once per day on days 1, 3, 5
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 2
- Cycles 2 to 6: 500 mg/m2 IV once on day 2
Supportive medications
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 7 of cycle 1
- Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO twice per day
- Antiviral prophylaxis with:
- EITHER Valacyclovir (Valtrex) 500 mg PO once per day
- OR Valganciclovir (Valcyte) 450 mg PO twice per day
- Pegfilgrastim (Neulasta) 6 mg SC once on day 6
- At physician's discretion:
- Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to Rituximab (Rituxan)/Alemtuzumab (Campath)
- Diphenhydramine (Benadryl) 25 to 50 mg IV or PO once 30 minutes prior to Rituximab (Rituxan)/Alemtuzumab (Campath)
- Hydrocortisone (Cortef) 100 mg IV once 30 minutes prior to Alemtuzumab (Campath)
28-day cycle for 6 cycles
References
- Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25;118(8):2085-93. Epub 2011 Jun 13. link to original article contains protocol link to PMC article PubMed
FluCam
back to top |
FluCam: Fludarabine, Campath
Regimen
Study | Evidence |
---|---|
Elter et al. 2005 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days 1 to 3
- Alemtuzumab (Campath) as follows:
- Cycle 1: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
- Cycles 2 to 6: 30 mg IV once per day on days 1 to 3
Supportive medications
- Trimethoprim/Sulfamethoxazole 960 mg (paper did not specify which component was 960 mg) PO once per day, started on day 1 and continued at least 2 months after treatment is complete
- Valacyclovir (Valtrex) 500 mg PO twice per day, started on day 1 and continued at least 2 months after treatment is complete
- If patients experienced CMV (cytomegalovirus) reactivation, valacyclovir was replaced by "oral or intravenous ganciclovir" 500 mg TID
- Fluconazole (Diflucan) 100 mg PO once per day, started if patients had evidence of fungal infection, continued until resolution
- Acetaminophen (Tylenol) 1000 mg PO once prior to first dose of Alemtuzumab (Campath), then with subsequent doses if clinically indicated
- Clemastine (Tavist) 2 mg IV once prior to first dose of Alemtuzumab (Campath), then with subsequent doses if clinically indicated
- Prednisone (Sterapred) 100 mg IV once prior to first dose of Alemtuzumab (Campath), then with subsequent doses if clinically indicated
- For patients with WBC count greater than 50 x 109/L, bulky disease, or history of hyperuricemia: Allopurinol (Zyloprim) 300 mg PO once prior to first dose of Alemtuzumab (Campath), and used later if clinically indicated
28-day cycle for 6 cycles
References
- Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6. link to original article contains protocol PubMed
Fludarabine & Prednisone
back to top |
Regimen
Study | Evidence |
---|---|
O'Brien et al. 1993 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV over 30 minutes once per day on days 1 to 5
- Prednisone (Sterapred) 30 mg/m2 PO once per day on days 1 to 5
28-day cycles
References
- O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993 Sep 15;82(6):1695-700. link to original article contains protocol PubMed
- Update: Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15;92(4):1165-71. link to original article PubMed
HDMP-R
back to top |
HDMP-R: High Dose, MethylPrednisolone, Rituximab
Variant #1, 3 cycles
Study | Evidence |
---|---|
Castro et al. 2008 | Phase II |
Chemotherapy
- Methylprednisolone (Solumedrol) 1000 mg/m2 IV over 90 minutes once per day on days 1 to 5
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 3, 5, 8, 17, 22
- Cycles 2 & 3: 375 mg/m2 IV once per day on days 1, 7, 14, 21
28-day cycle for 3 cycles
Variant #2, 6 cycles
Study | Evidence |
---|---|
Pileckyte et al. 2011 | Phase II |
Chemotherapy
- Methylprednisolone (Solumedrol) 1000 mg/m2 IV over 4 hours once per day on days 1 to 5
- Rituximab (Rituxan) as follows:
- Cycle 1: 50 mg IV once on day 1, then 150 mg IV once on day 2, then remainder of a 375 mg/m2 dose on day 3, then 500 mg/m2 IV once on day 5
- Cycles 2 to 6: 500 mg/m2 IV once per day on days 1 & 5
Supportive medications
- Trimethoprim/sulfamethoxazole "or an equivalent antibiotic throughout the treatment period and up to 6 months after the completion of therapy"
21-day cycle for 6 cycles
References
- Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008 Nov;22(11):2048-53. Epub 2008 Aug 28. link to original article link to PMC article contains verified protocol PubMed
- Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, Sejoniene J, Degulys A, Zvirblis T, Griskevicius L. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Jun;52(6):1055-65. link to original article contains protocol PubMed
Ibrutinib & Ofatumumab
back to top |
Variant #1, concurrent ibrutinib and ofatumumab
Study | Evidence |
---|---|
Jaglowski et al. 2015 | Phase II |
This study to patients who had failed two or more prior therapies, or had Richter's transformation.
Chemotherapy
- Ibrutinib (Imbruvica) 420 mg PO once per day
- Ofatumumab (Arzerra) as follows:
- Dose 1: 300 mg IV once on day 1
- Doses 2 to 8: 2000 mg IV once per week on weeks 2 to 8
- Doses 9 to 12: 2000 mg IV once per month on weeks 13, 17, 21, 25
One course; ibrutinib given until progression of disease or unacceptable toxicity
Variant #2, ibrutinib lead-in
Study | Evidence |
---|---|
Jaglowski et al. 2015 | Phase II |
This study to patients who had failed two or more prior therapies, or had Richter's transformation.
Chemotherapy
- Ibrutinib (Imbruvica) 420 mg PO once per day
- Ofatumumab (Arzerra) as follows:
- Dose 1: 300 mg IV once on week 5
- Doses 2 to 8: 2000 mg IV once per week on weeks 6 to 12
- Doses 9 to 12: 2000 mg IV once per month on weeks 17, 21, 25, 29
One course; ibrutinib given until progression of disease or unacceptable toxicity
Variant #3, ofatumumab lead-in
Study | Evidence |
---|---|
Jaglowski et al. 2015 | Phase II |
This study to patients who had failed two or more prior therapies, or had Richter's transformation.
Chemotherapy
- Ibrutinib (Imbruvica) 420 mg PO once per day, starting on week 9
- Ofatumumab (Arzerra) as follows:
- Dose 1: 300 mg IV once on day 1
- Doses 2 to 8: 2000 mg IV once per week on weeks 2 to 8
- Doses 9 to 12: 2000 mg IV once per month on weeks 13, 17, 21, 25
One course; ibrutinib given until progression of disease or unacceptable toxicity
References
- Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015 Aug 13;126(7):842-50. Epub 2015 Jun 26. link to original article contains verified protocol link to PMC article PubMed
Ibrutinib & Rituximab
back to top |
Regimen
Study | Evidence |
---|---|
Burger et al. 2014 | Phase II |
This study was open to patients with high-risk CLL (del17p or TP53 mutation, PFS less than 36 months from initial therapy, or relapsed CLL with del11q). Only 4 patients in the published study were untreated.
Chemotherapy
- Ibrutinib (Imbruvica) 420 mg PO once per day
- Rituximab (Rituxan) 375 mg/m2 IV once per week for 4 weeks, then once per month until cycle 6
28-day cycles; ibrutinib given until progression of disease or unacceptable toxicity
References
- Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep;15(10):1090-9. Epub 2014 Aug 20. link to original article contains verified protocol link to PMC article PubMed
- Update: Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia. Clin Cancer Res. 2017 May 1;23(9):2154-2158. Epub 2016 Oct 19. link to original article link to PMC article PubMed
Idelalisib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Gopal et al. 2014 (DELTA) | Phase II |
Brown et al. 2014 | Phase I, >20 pts |
Chemotherapy
- Idelalisib (Zydelig) 150 mg PO twice per day
Continued until progression, death, or unacceptable toxicity
References
- DELTA: Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. Epub 2014 Jan 22. link to original article contains verified protocol link to PMC article PubMed
- Update: Abstract: Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 link to abstract
- Phase 1: Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7. Epub 2014 Mar 10. link to original article link to PMC article PubMed
Lenalidomide monotherapy
back to top |
Variant #1
Study | Evidence |
---|---|
Chanan-Khan et al. 2006 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 5 mg PO once per day, escalated by 5 mg every 1 to 2 weeks to a target maximum dose of 25 mg PO once per day on days 1 to 21
Supportive medications
- Allopurinol (Zyloprim) 300 mg PO once per day, starting 2 to 3 days prior to therapy, and continued up to a total of 14 days
28-day cycles
Variant #2
Study | Evidence |
---|---|
Ferrajoli et al. 2008 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 10 mg PO once per day, then increased by 5 mg every 28 days to a target maximum dose of 25 mg PO once per day
28-day cycles
Variant #3
Study | Evidence |
---|---|
Witzig et al. 2009 (NHL-001) | Phase II, <20 patients in this subgroup |
Patients studied in this trial and in this subgroup had a diagnosis of SLL.
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
28-day cycles until disease progression or unacceptable toxicity
References
- Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6. link to original article contains protocol PubMed
- Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 1;111(11):5291-7. Epub 2008 Mar 11. link to original article link to PMC article PubMed
- Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5404-9. Epub 2009 Oct 5. link to original article contains verified protocol PubMed
Lenalidomide & Ofatumumab
back to top |
Variant #1
Study | Evidence |
---|---|
Vitale et al. 2016 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 10 mg PO once per day, starting on day 9 of cycle 1
- Ofatumumab (Arzerra) as follows:
- Cycle 1: 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
- Cycles 3 to 6: 1000 mg IV once on day 1
- Cycles 7 to 24: 1000 mg IV once on day 1 of every other cycle
Supportive medications
- Allopurinol (Zyloprim) 300 mg PO once per day on days 1 to 14 of cycle 1
- G-CSF use allowed per 2006 ASCO guidelines
- "No anti-infectious, venous thromboembolism (VTE), or TFR prophylaxis was mandated"
28-day cycle for 24 cycles
Patients with a sustained PR or CR were allowed to continue treatment with lenalidomide monotherapy indefinitely.
References
- Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res. 2016 May 15;22(10):2359-67. Epub 2016 Jan 5. link to original article contains verified protocol link to PMC article PubMed
Lenalidomide & Rituximab
back to top |
Variant #1
Study | Evidence |
---|---|
Chanan-Khan et al. 2006 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 5 mg PO once per day, escalated by 5 mg every 1 to 2 weeks to a target maximum dose of 25 mg PO once per day on days 1 to 21
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15
- Subsequent Cycles: 375 mg/m2 IV once per day on days 1 & 15
Supportive medications
- Allopurinol (Zyloprim) 300 mg PO once per day, starting 2 to 3 days prior to therapy, and continued up to a total of 14 days
28-day cycles
Variant #2
Study | Evidence |
---|---|
Badoux et al. 2013 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) as follows:
- Cycle 1: 10 mg PO once per day on days 9 to 28
- Subsequent Cycles: 10 mg PO once per day on days 1 to 28
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once per day on days 1, 8, 15, 22
- Cycle 2: no rituximab given
- Cycles 3 to 12: 375 mg/m2 IV once on day 1
Supportive medications
- Allopurinol (Zyloprim) (dose/schedule not specified) on days 1 to 14 of cycle 1
- No mandatory antibacterial, antiviral, DVT, or tumor flare prophylaxis
- Growth factor use allowed per 2006 ASCO guidelines
28-day cycle for 12 cycles
Lenalidomide could continue indefinitely in responders.
References
- Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6. link to original article contains protocol PubMed
- Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2013 Feb 10;31(5):584-91. Epub 2012 Dec 26. link to original article contains verified protocol link to PMC article PubMed
Obinutuzumab monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Cartron et al. 2014 (GAUGUIN) | Phase II |
Note: Dose here is the phase II dose
Chemotherapy
- Obinutuzumab (Gazyva) as follows:
- Cycle 1: 1000 mg IV once per day on days 1, 8, 15
- Cycle 2 onwards: 1000 mg IV once on day 1
Supportive medications
- Acetaminophen (Tylenol) 650 to 1000 mg PO 30 minutes prior to first infusion, repeat for those at risk of tumor lysis or with history of reaction
- Antihistamine (no drug or dose specified) PO 30 minutes prior to first infusion, repeat for those at risk of tumor lysis or with history of reaction
- Corticosteroids (no drug/dose/route specified) before first infusion for patients at "high risk" of severe infusion reaction, including those with a history of severe Rituximab (Rituxan) reactions
21-day cycle up to 10 doses (8 cycles)
References
- Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014 Oct 2;124(14):2196-202. Epub 2014 Aug 20. link to original article contains verified protocol PubMed
OFAR
back to top |
OFAR: Oxaliplatin, Fludarabine, Ara-C (Cytarabine), Rituximab
Regimen
Study | Evidence |
---|---|
Tsimberidou et al. 2008 | Phase II |
Chemotherapy
- Oxaliplatin (Eloxatin) 25 mg/m2 IV over 2 hours once per day on days 1 to 4
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days 2 & 3, administered within 30 minutes of completion of oxaliplatin
- Cytarabine (Cytosar) 1000 mg/m2 IV over 2 hours once per day on days 2 & 3, 4 hours after fludarabine started
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV over 4 to 6 hours once on day 3
- Cycles 2 to 6: 375 mg/m2 IV over 4 to 6 hours once on day 1
Supportive medications
- Pegfilgrastim (Neulasta) 6 mg SC once on day 6
- Herpes zoster and PCP (Pneumocystis jiroveci pneumonia) prophylaxis used
28-day cycle for up to 6 cycles
References
- Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10;26(2):196-203. link to original article contains protocol PubMed
PCR
back to top |
PCR: Pentostatin, Cyclophosphamide, Rituximab
Regimen
Study | Evidence |
---|---|
Lamanna et al. 2006 | Phase II |
Chemotherapy
- Pentostatin (Nipent) 4 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
- Rituximab (Rituxan) as follows:
- Cycle 1: no dose
- Cycles 2 to 6: 375 mg/m2 IV once on day 1
Supportive medications
- Note: paper says they were "administered prophylactically," without additional details.
- Filgrastim (Neupogen)
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Acyclovir (Zovirax)
21-day cycle for 6 cycles
References
- Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 1;24(10):1575-81. Epub 2006 Mar 6. link to original article contains protocol PubMed
R-BAC
back to top |
R-BAC: Rituximab, Bendamustine, Ara-C (Cytarabine)
Regimen
Study | Evidence |
---|---|
Visco et al. 2013 | Pilot, <20 patients reported |
Chemotherapy
- Rituximab (Rituxan) as follows:
- Cycle 1: 375 mg/m2 IV once on day 1
- Subsequent cycles: 500 mg/m2 IV once on day 1
- Bendamustine 70 mg/m2 IV once per day on days 1 & 2
- Cytarabine (Cytosar) 800 mg/m2 IV over 2 hours once per day on days 1 to 3, beginning 2 hours after bendamustine
Supportive medications
- Primary prophylaxis with granulocyte colony-stimulating factor was routinely used starting from Day 5 after chemotherapy completion, and lasting for 3 to 6 days or until neutrophil count recovery.
28-day cycle for up to 4 cycles with dose delay and modification based on response and toxicity
References
- Visco C, Finotto S, Pomponi F, Sartori R, Laveder F, Trentin L, Paolini R, Di Bona E, Ruggeri M, Rodeghiero F. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. Am J Hematol. 2013 Apr;88(4):289-93. Epub 2013 Feb 28. link to original article contains verified protocol PubMed
Ruxolitinib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Jain et al. 2017 | Phase II, <20 pts in this subgroup |
Note: this was a trial focused on symptom control, not efficacy.
Chemotherapy
- Ruxolitinib (Jakafi) 10 mg PO twice per day
References
- Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb;4(2):e67-e74. Epub 2017 Jan 11. link to original article contains protocol link to PMC article PubMed
Venetoclax monotherapy
back to top |
Variant #1, standard lead-in
FDA-recommended dose |
Study | Evidence | Efficacy |
---|---|---|
Roberts et al. 2015 (M12-175) | Phase I/II | ORR: 79% |
Stilgenbauer et al. 2016 (M13-982) | Phase II | ORR: 79% (95% CI, 70.5-87) |
Coutre et al. 2018 (M14-032) | Phase II | ORR: 67% |
This is the dosing schedule used in the phase II expansion cohort of Roberts et al. 2015. See paper for supportive care details during initial dosing.
Chemotherapy
- Venetoclax (Venclexta) as follows:
- Week 1: 20 mg PO once per day
- Week 2: 50 mg PO once per day
- Week 3: 100 mg PO once per day
- Week 4: 200 mg PO once per day
- Week 5 onwards: 400 mg PO once per day
Continued until disease progression or unacceptable toxicity
Variant #2, modified lead-in
Study | Evidence | Efficacy |
---|---|---|
Coutre et al. 2018 (M14-032) | Phase II | ORR: 67% |
This dosing schedule was intended for high-risk patients with "clinical signs of progression during screening." See paper for supportive care details during initial dosing.
Chemotherapy
- Venetoclax (Venclexta) as follows:
- Day 1: 20 mg PO once per day
- Days 2 & 3: 50 mg PO once per day
- Days 4 to 7: 100 mg PO once per day
- Week 2: 200 mg PO once per day
- Week 3 onwards: 400 mg PO once per day
Continued until disease progression or unacceptable toxicity
References
- M12-175: Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311-22. Epub 2015 Dec 6. link to original article contains verified protocol PubMed
- M13-982: Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Heitner Enschede S, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-78. Epub 2016 May 10. link to original article contains protocol PubMed
- Update: Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. Epub 2018 May 1. PubMed
- M14-032: Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 Apr 12;131(15):1704-1711. Epub 2018 Jan 5. link to original article contains verified protocol in supplement PubMed
Consolidation and/or maintenance after subsequent lines of therapy
FC, then allo HSCT
back to top |
FC: Fludarabine & Cyclophosphamide
Regimen
Study | Evidence |
---|---|
Dreger et al. 2010 (GCLLSG CLL3X) | Phase II |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days -6 to -2 (5 consecutive days)
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days -6 to -2 (5 consecutive days)
GVHD prophylaxis
- ATG-Fresenius by the following donor-based criteria:
- Unrelated donors: 10 mg/kg/day IV on days -4 to -1 (4 consecutive days)
Immunotherapy
- Allogeneic stem cells transfused on day 0
One course
References
- GCLLSG CLL3X: Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438-47. Epub 2010 Jul 1. link to original article contains verified protocol PubMed
- Update: Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 Apr 18;121(16):3284-8. Epub 2013 Feb 22. link to original article PubMed
- Update: Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477-1480. Epub 2017 Jul 17. link to original article PubMed
Fludarabine & TBI, then allo HSCT
back to top |
Regimen
Study | Evidence |
---|---|
Sorror et al. 2005 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days -4 to -2
Radiotherapy
- Total body irradiation (TBI) 200 cGy at a rate of 7 cGy/min on day 0
Immunotherapy
- Allogeneic stem cells transfused on day 0
GVHD prophylaxis
- Cyclosporine 6.25 mg/kg PO twice per day starting 4 to 6 hours after transplant, tapered at day 100 over 80 days (if no GVHD)
- Mycophenolate mofetil (CellCept) 15 mg/kg PO twice per day starting 4 to 6 hours after transplant, tapered at day 40 over 56 days (if no GVHD)
One course
References
- Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 1;23(16):3819-29. Epub 2005 Apr 4. link to original article PubMed
- Update: Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher MA, McSweeney PA, Wade JC, Bruno B, Langston A, Radich J, Niederwieser D, Blume KG, Storb R, Maloney DG. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008 Oct 20;26(30):4912-20. Epub 2008 Sep 15. link to original article link to PMC article PubMed
Fludarabine, Busulfan, ATG, then allo HSCT
back to top |
Regimen
Study | Evidence |
---|---|
Slavin et al. 1998 | Phase II |
Schetelig et al. 2003 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days -10 to -5 (6 consecutive days)
- Busulfan (Myleran) 4 mg/kg/day PO on days -6 to -5 (2 consecutive days)
GVHD prophylaxis
- ATG-Fresenius 10 mg/kg IV once per day on days -4 to -1 (4 consecutive days)
Immunotherapy
- Allogeneic stem cells transfused on day 0
One course
References
- Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63. link to original article contains verified protocol PubMed
- Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003 Jul 15;21(14):2747-53. link to original article contains reference to protocol PubMed
Fludarabine, Cyclophosphamide, ATG, then allo HSCT
back to top |
Regimen
Study | Evidence |
---|---|
Dreger et al. 2010 (GCLLSG CLL3X) | Phase II |
References
- GCLLSG CLL3X: Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010 Oct 7;116(14):2438-47. Epub 2010 Jul 1. link to original article contains verified protocol PubMed
- Update: Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 Apr 18;121(16):3284-8. Epub 2013 Feb 22. link to original article PubMed
- Update: Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 Sep 21;130(12):1477-1480. Epub 2017 Jul 17. link to original article PubMed
Observation
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
van Oers et al. 2015 (PROLONG) | Phase III (C) | Ofatumumab | Inferior PFS |
Greil et al. 2016 (AGMT CLL-8a) | Phase III (C) | Rituximab | Inferior PFS |
No further treatment offered to patients in their second or third CR or PR; prior treatment was not specified in PROLONG.
Preceding treatment
- AGMT CLL-8a: "Rituximab-containing chemoimmunotherapy"
References
- PROLONG: van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Gupta I, Phillips J, Williams V, Manson S, Lisby S, Geisler C; PROLONG study investigators. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015 Oct;16(13):1370-9. Epub 2015 Sep 13. link to original article contains verified protocol PubMed
- AGMT CLL-8a: Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. link to original article contains protocol PubMed
Ofatumumab monotherapy
back to top |
Variant #1
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
van Oers et al. 2015 (PROLONG) | Phase III (E) | Observation | Superior PFS |
Treatment offered to patients in their second or third CR or PR; prior treatment was not specified.
Chemotherapy
- Ofatumumab (Arzerra) 300 mg IV once, then 1000 mg IV one week later and every 8 weeks
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO 30 to 120 minutes prior to each infusion
- Diphenhydramine (Benadryl) 50 mg IV or PO 30 to 120 minutes prior to each infusion, or equivalent antihistamine
- Prednisolone (Millipred) 50 mg IV 30 to 120 minutes prior to each infusion, or equivalent glucocorticoid
Up to 2-year course
Variant #2
Study | Evidence |
---|---|
Österborg et al. 2015 (GEN416) | Phase II |
Preceding treatment
- Ofatumumab x 8
Chemotherapy
- Ofatumumab (Arzerra) 2000 mg IV once per month
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO once prior to each infusion
- Cetirizine (Zyrtec) (or equivalent antihistamine) 10 mg PO once prior to each infusion
Up to 2 years (24 doses)
References
- GEN416: Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2015 Jul;170(1):40-9. Epub 2015 Mar 30. link to original article contains verified protocol PubMed
- PROLONG: van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Gupta I, Phillips J, Williams V, Manson S, Lisby S, Geisler C; PROLONG study investigators. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015 Oct;16(13):1370-9. Epub 2015 Sep 13. link to original article contains verified protocol PubMed
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Chanan-Khan et al. 2017 (CONTINUUM) | Phase III (C) | Lenalidomide | Seems not superior |
No active antineoplastic treatment offered to patients with at least partial response to second-line therapy.
References
- CONTINUUM: Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Foà R. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017 Nov;4(11):e534-e543. Epub 2017 Sep 25. link to original article PubMed
Rituximab monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Greil et al. 2016 (AGMT CLL-8a) | Phase III (E) | Observation | Superior PFS |
Preceding treatment
- "Rituximab-containing chemoimmunotherapy"
Chemotherapy
- Rituximab (Rituxan) 375 mg/m2 IV once every 3 months
2 years total (8 doses)
References
- AGMT CLL-8a: Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. Epub 2016 Jun 16. link to original article contains protocol PubMed
Prognosis
These are various staging and risk prediction systems that are in approximate chronological order.
Original Rai staging (1975)
back to top |
- Stage 0: bone marrow and blood lymphocytosis only
- Stage I: lymphocytosis with enlarged nodes
- Stage II: lymphocytosis with enlarged spleen or liver or both
- Stage III: lymphocytosis with anemia
- Stage IV: lymphocytosis with thrombocytopenia
- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34. link to original article PubMed
Binet staging (1981)
back to top |
- Group A: no anemia, no thrombocytopenia, less than three involved areas
- Group B: no anemia, no thrombocytopenia, three or more involved areas (counting as one each of the following: axillary, cervical, inguinal, lymph nodes, whether unilateral or bilateral, spleen and liver)
- Group C: anemia (hemoglobin less than 10 g/dL) and/or thrombocytopenia (platelets less than 100 x 109/L)
- Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198-206. link to original article PubMed
Risk by karyotype (1984)
back to top |
Classic NEJM paper establishing abnormal karyotype as an adverse prognostic marker
- Han T, Ozer H, Sadamori N, Emrich L, Gomez GA, Henderson ES, Bloom ML, Sandberg AA. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N Engl J Med. 1984 Feb 2;310(5):288-92. to original article PubMed
Risk by lymphocyte doubling time
- Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986 Mar;62(3):567-75. link to original article PubMed
- Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 1987 Dec 1;60(11):2712-6. link to original article PubMed
Risk by FISH
back to top |
- Classic 2000 NEJM paper establishing that 17p deletion has the worst prognosis:
- Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 28;343(26):1910-6. link to original article PubMed
- This article and abstract explore the significance of 13q deletions in more detail:
- Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol. 2010 Feb;148(4):544-50. Epub 2009 Nov 6. link to original article link to PMC article PubMed
- Abstract: Claudia Haferlach, Melanie Zenger, Vera Grossmann, Frank Dicker, Sabine Jeromin, Alexander Kohlmann, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach. The Impact of Homozygosity and Size of the 13q Deletion in Patients with CLL. Blood 2012 120:3892 abstract 3892 link to abstract
Risk by TP53 mutation
back to top |
- Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010 Oct 10;28(29):4473-9. Epub 2010 Aug 9. link to original article PubMed
Risk by CD38 expression
back to top |
- Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1840-7. link to original article PubMed
- Review: Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011 Sep 29;118(13):3470-8. link to original article link to PMC article PubMed
Risk by ZAP-70 expression (2003)
back to top |
- Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003 May 1;348(18):1764-75. link to original article PubMed
Prognostic scoring system using molecular and cytogenetic features (2012)
back to top |
- Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, Pasqualucci L, Rabadan R, Foà R, Dalla-Favera R, Gaidano G. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013 Feb 21;121(8):1403-12. Epub 2012 Dec 13. link to original article link to PMC article PubMed
CLL-IPI (2016)
back to top |
- International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016 Jun;17(6):779-90. Epub 2016 May 13. link to original article PubMed